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The growth plate is a cartilaginous tissue responsible for the longitudinal growth of long 
bones.  It is a complex tissue composed of chondrocytes whose maturation and 
proliferation is tightly regulated by a biochemical feedback loop.  Injury to this tissue can 
result in a limb length discrepancy or angular deformity that may lead to life long 
disability.  Given the recent rise in the number of growth plate injuries and the variability 
in success of current therapies, there is a significant need for a greater understanding of 
growth plate injury pathology and the development of improved treatment strategies.   
Cartilage tissue engineering strategies offer an attractive alternative to 
regenerating growth plate tissue and restoring growth function.  Bone  marrow-derived 
stem cells (BMSCs) have been shown to be able to undergo chondrogenic differentiation 
and in vitro and in vivo and therefore offers an appealing and abundant cell resource for 
developing tissue engineering strategies for the treatment of growth plate defects.  
However, the dependence of chondrogenic differentiation and matrix accumulation on 
monolayer  expansion protocols and three-dimensional (3D) culture environment has 
received little attention. 
Prior to developing treatment strategies for growth plate injury repair, it is 
essential to first understand the interconnection between alterations in growth plate 
morphology and subsequent limb deformities.  To that end, we have established a 
surgical defect model of growth plate injury in Sprague Dawley rats and developed a 
novel technique to quantitatively monitor growth plate morphology in health and disease 
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using microcomputed tomography (micro-CT) imaging.  In an effort to develop a tissue 
engineering treatment strategy for growth plate injury, the role of monolayer expansion, 
3D scaffold, and growth factor regimen in the chondrogenic differentiation of rat BMSCs 
was also examined.  This research study has demonstrated the utility of micro-CT as a 
non-invasive imaging modality for assessing growth plate injury and repair.  This work 
has also provided an improved understanding of the interrelationship of monolayer 
expansion, 3D culture environment, and growth factor regimen in BMSC chondrogenic 
differentiation.  Finally, this work suggests that an injectable in situ gelling hydrogel is a 
feasible method for decreasing limb length discrepancies, however, neither implantation 









In response to injury to the growth plate, an influx of vasculature and progenitor 
cells from the bone marrow cavity may stimulate the formation of a bone bridge 
(epiphysiodesis) through all or part of the growth plate.  This often results in a loss in 
growth function and premature closure of the growth plate and, ultimately, limb length 
discrepancies or angular deformity.  Current treatment includes excision of the bone 
bridge and interposition of a filler material, typically autologous fat.  However, the 
clinical outcome of these procedures is highly variable, ranging from a 15-38% success 
rate [1].   Large transphyseal bone bridges cannot be treated by interposition of fat and 
eventually, once skeletal maturity occurs, treatment of the discrepancy in limb length 
may require highly invasive limb lengthening procedures.   
Research in this area has focused on developing tissue engineering techniques to 
treat this type of injury.  Before repair of the growth plate can be achieved, however, 
understanding the consequences of injury on growth plate and whole bone morphology 
must be determined.  Previously, this has been accomplished using radiographic and 
histomorphometric analysis, which is semi-quantitative at best.  The objective of the 
research was to develop a small animal growth plate defect model in Sprague Dawley rats 
to examine the efficacy of cartilage tissue engineering strategies in treating growth plate 
defects and to use microcomputed tomography (micro-CT) to quantitatively evaluate 
changes in growth plate and whole bone morphology.  Our goal was to not only prevent 
bone bridge formation within growth plate defects, but also to restore growth function by 
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employing a combination of scaffold and pluripotent marrow-derived stromal cells. The 
specific aims were to: 
I. To develop a small animal growth plate defect injury model in Sprague 
Dawley rats that exhibits clinical features of growth plate injury in humans.   
Rats have been widely used to study the fracture healing, osteoporosis, 
radiation effects on growth plate morphology, and, more recently, to study the 
biomolecular events of growth plate defect healing.  We used micro-CT and 
histological techniques to detect morphological changes in growth plate 
morphology and bone length over time in response to a centralized growth plate 
defect created in the distal femurs of Sprague Dawley rats.  We hypothesized that 
a centralized  defect would mimic the limb length discrepancy seen in pediatric 
cases of growth plate injury. 
II. To identify in vitro culture conditions to reproducibly induce chondrogenesis 
in Sprague Dawley rat bone marrow derived stem cells in 3D hydrogel 
constructs.   
Stem cells offer an attractive and abundant source of cells for 
osteochondral tissue engineering.  It is becoming more evident that  growth 
factors delivered in series or combination enhance gene expression and enhance 
matrix deposition of chondrogenic factors [1-4].  It has also been noted that the 
degree of monolayer expansion (passaging) has an effect on their differentiation 
potential [1, 2]. We hypothesized that Sprague Dawley rat bone marrow derived 
stem cells (BMSCs) can be induced to undergo chondrogenesis when exposed to a 
specific combination of growth factors including fibroblastic growth factor-2 
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(FGF-2) and transforming growth factor beta 1 (TGF-β1) in three-dimensional 
(3D) hydrogel scaffolds and that their differentiation potential was passage 
dependent.   
III. To test the ability of hydrogel constructs implanted into transphyseal defects 
to inhibit growth plate fusion and restore growth plate function. 
Blocking bone bar formation in growth plate defects is the major feature 
of current clinical treatment methods of this type of injury.  This may be achieved 
using an material that is injectable and polymerizes in situ.  The inclusion of cells 
has been shown to restore a growth plate phenotype to the injured area, but not to 
fully correct growth disturbance.  Therefore, we hypothesized that:  1)  injection 
of an in situ gelling agarose in centralized defects in the distal femurs of Sprague 
Dawley rats will inhibit limb length shortening caused by a growth plate defect by 
reducing bone bridge formation through the defect region and 2) delivery of 
stromal cells that have been pre-differentiated down the chondrogenic pathway 
into a growth plate defect will decrease limb length discrepancies and restore 




BACKGROUND AND LITERATURE REVIEW 
 
Growth Plate Structure and Function 
 
The growth plate is a cartilage-like tissue that is responsible for the elongation of 
long bones during childhood and adolescence through a process known as endochondral 
ossification (EO).  The growth plate can be divided into five zones: resting cell zone, 
proliferative cell zone, prehypertrophic cell zone, hypertrophic cell zone, and calcified 
cartilage (Figure 2.1).  In the resting zone, a small number of relatively quiescent cells 
are embedded in a matrix rich in aggrecan and collagen type II.  As they further 
differentiate and enter the proliferative zone, cells are rapidly dividing, flattened, and 
arranged in columns.  During the transition from the proliferating phenotype into the 
prehypertrophic zone, cells begin to enlarge.  In the hypertrophic zone, the cells undergo 
a 5-10 fold increase in intracellular volume (responsible for 44-59% of long bone 
growth), secrete a specialized matrix including collagen type X, and express high levels 
of alkaline phosphatase (ALP).  The final stage of chondrocyte maturation is terminal 
differentiation during which the extracellular matrix is mineralized and the cells undergo 
apoptosis.  This process leaves a calcified scaffold onto which osteoblasts brought in by 
invading vasculature lay down primary bone.  During EO, this calcified cartilage is later 
remodeled into secondary trabeculae [2, 3].   
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Figure 2.1.  Schematic of  the epiphysis of long bones. 
The outset image of the growth plate is a histological section stained with hematoxylin 
and eosin.  The resting zone cells are sporadically distributed throughout a collagen type 
II and aggrecan rich matrix.  The proliferative cells are arranged in columns and have a 
flattened appearance.  In the prehypertrophic zone, the cells are beginning to separate and 
secrete matrix.  The large hypertrophic cells are visible above the vertical struts of 
calcified cartilage covered with new bone (arrow). 
 
 
Recent studies have shed considerable light on the molecular regulation of 
endochondral ossification and revealed remarkable similarities in the mechanisms of fetal 
development and adult fracture repair [4].  The maturation of chondrocytes through each 
zone of the growth plate is tightly controlled through a feedback loop formed from the 
interaction of specific autocrine and paracrine signaling molecules synthesized by the 
chondrocytes.  The predominant factors in the feedback loop that regulate cell maturation 
in the growth plate are parathyroid hormone related protein (PTHrP), Indian hedgehog 
(Ihh), and transforming growth factor – β (TGF-β).  Prehypertrophic cells secrete Ihh in 
response to bone morphogenetic protein – 6 (BMP-6) secreted by hypertrophic cells.  Ihh 
stimulates the cells of the perichondrium to release TGF-β.  TGF-β then acts on the cells 
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of the perichondrium and appositional cartilage cells to increase expression of PTHrP.  In 
response to increased PTHrP synthesis, the number of prehypertrophic cells expressing 
Ihh decreases.  As the hypertrophic cells reach terminal differentiation and undergo 
apoptosis, the late prehypertrophic cells mature to hypertrophy and begin to secrete 
BMP-6 [5, 6].  A simplified model of this pathway is outlined in (Figure 2.2).  In 
addition to the aforementioned factors, there is also evidence that chondrocyte phenotype 
is modulated by other systemic and local signaling molecules including the bone 
morphogenetic proteins (BMPs), the insulin-like growth factors (IGF)/growth hormone 






   Resting Zone 
      Proliferative 
     Ihh; PTHrP-R 















Growth Plate Injury 
 
Approximately 42% of male children and 27% of female children experience a 
broken bone by the age of 16 and it is estimated that 20% of these fractures will involve 
the growth plate [12-14].  Injury to the growth plate may result in full or partial closure of 
the epiphysis through the formation of a mineralized bone bridge through the defect 
region that connects the epiphyseal bone to the metaphysis [14-16].   In addition to 
damage during fracture, injury to the growth plate may also result from the removal of 
osteosarcomas, the treatment of bone cysts, diabetes, chemotherapy, juvenile arthritis, 
and limb stabilization in the case of osteopetrosis imperfecta [17-20].  Damage to 
epiphyseal cartilage may result in an angular deformity if the injury occurs within the 
peripheral regions of the tissue and in a limb length discrepancy if the defect is centrally 
located [15, 21].  Abnormal loading due to these joint incongruities may cause life-long 
disabilities [16]. 
There are several classification systems for growth plate injury [22, 23], but the 
standard system used was developed by Salter and Harris in 1963 (Figure 2.3) [24].  
Type I fractures involve the growth plate, but not the epiphyseal or metaphyseal bone.  In 
Type II fractures, the line of fracture is through the growth plate and extends through the 
metaphysis breaking off a triangular piece of bone.  Type III fractures run vertically 
through the epiphyseal bone and obliquely through a portion of the growth plate.   Type 
IV fractures are due to vertically oriented splitting compression forces and cause a 
fracture of both the epiphysis and metaphysis.  These fractures cannot be seen in 
radiographs.  Types IV and V typically lead to growth disruption and although type V 
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injuries are quite rare, they are the most devastating due to destruction of the 
hypertrophic zone [14, 25, 26].  Premature fusion of the growth plate is more common in 
the distal femur and tibia regardless of how the injury was obtained.  The distal femur is 
infrequently injured, but has the highest incidence of premature closure in case studies 
[14, 16].  Because this region contributes 55-70% of overall growth to the femur, 
premature fusion of this area can result in significant shortening of the limb [16].   
 
I II III IV V 
 
   
 
6-9% 73-75% 6.5-8% 10-12% >1% 
      
Figure 2.3.  Salter-Harris classification of growth plate defects. 
Red lines indicate plane of fracture.  Values beneath each image is the frequency of 
occurrence [14] 
 
Imaging of Growth Plate Injury 
 
One of the major challenges with growth plate injury treatment is diagnosing the 
morphology of the growth plate after injury.  Radiographical analysis (x-rays) is the first 
mode of analysis in the clinic, but images are hard to interpret and not all bridges, 
especially fibrous ones, will be visible [27, 28].  Diagnosis is based on epiphyseal 
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displacement or widening and haziness of the epiphyseal and metaphyseal margin along 
the growth plate [14].   
Currently, the most common analysis method used in the clinical setting is 
magnetic resonance imaging (MRI) with fat-suppressed 3D spoiled gradient-recalled 
echo [27, 29-32].  Using this technique, the growth plate appears in intense contrast to the 
surrounding bone [14].  Defects within the growth plate, whether they be filled with bony 
or fibrous tissue, appear as a dark disruption within the tissue [14].  Recently, methods 
for 3D reconstruction of injured epiphyses from MR images have been developed [27, 
29-31], however, this technique remains an expensive and time-consuming method with 
lower resolution than CT technologies [31].  Additionally, children under six years of age 
must be sedated for MR imaging [32].  It has also been noted that some coronal and 
sagittal images of the normal knee show discontinuity of the physeal cartilage (drop-out 
sign), which may be mistaken for premature closure [33, 34], and clinicians may have to 
wait up to 8 months before a bone bridge is apparent in a MR image [35].   
Computed tomography (CT) images are used to fully evaluate growth plate 
injuries that have been found by radiographic analysis [14].  Methods to create joint 3D 
models of fractured epiphyses are in practice to aide in surgical planning for fractures, 
slipped femoral epiphyses, and bone bridge removal [14, 36, 37].  
 
Treatment of Growth Plate Injury 
 
Acute injuries that traverse the growth plate (Salter types III and IV) typically 
result in the formation of a bony bridge that is visible on radiomicrographs and MR 
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images [27, 28].  The most common treatment of minor growth plate injuries – those 
where the bone bridge size is <40% of the growth plate and the prospective growth 
period is at least 2 years – is the Langenskiöld procedure [1].  It involves removal of the 
bone bridge and insertion of autologous fat into the empty space to prevent reformation 
of the bone bridge.  The fat is typically sutured to the growth plate or perichondrium to 
prevent migration of the graft.  This procedure is labor intensive and, despite 
standardization of the technique in the field, clinical success is unpredictable, ranging 
from 15-38% [1].  Fat is prone to bone reformation after bleeding at the graft surface, 
fibrous degeneration and shrinking, dislocation of the graft, or necrosis in the center of 
the graft [1, 38, 39].  Alternate materials have been interposed in the defect including 
frozen hyaline cartilage, iliac apophysis, and nonbiologic materials such as 
methylmethacrylate, bone wax, and silastic [38, 40].  Although cartilage is reported to be 
more effective than fat in preventing growth retardation and angular deformity, none of 
the aforementioned materials fully restores function to the growth plate [39, 41]. 
For severe deformities, an alternative method, microsurgically revascularized 
epiphyseal plate transfer, is utilized.  Here, a section of autologous growth plate and flap 
of skin is transferred from another anatomical site to the injured area and the vasculature 
from the skin is anastamosed to major blood vessels in the surrounding recipient site.  
The most common anatomical sites for growth plate harvest are the head of the fibula, 
lower scapula, and iliac crest [42, 43].  While this procedure does restore growth function 
to the growth plate by ensuring adequate blood flow to the area, a requirement for proper 
endochondral ossification, it is complex and labor intensive, the growth rate of the 
epiphysis is site dependent [44], donor site morbidity is prevalent [42, 44], and 
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transplanted growth plates do not adapt easily to the recipient site [42, 43, 45, 46].  In the 
case of allogenic epiphyseal graft transfer, immunosupression is required to restore 
growth function.  However, the administration of a immunosuppressive regimen in non-
life threatening situations is still controversial [44].  Therefore, limb discrepancies or 
angular deformities may still occur and distraction osteogenesis following skeletal 
maturity may be indicated.   
More recently, a technique of slow distraction of the growth plate termed 
chondrodiastasis or hemi-chondrodiastasis has been developed to correct angular 
deformities [25].  In a rabbit animal model, Lee et al. demonstrated that this technique 
was able to correct angular deformities without having to remove the bone bridge [47]. 
 
Growth Plate Injury Animal Models 
 
Several animal models of growth plate injuries have been developed and used to 
test clinical approaches to growth plate repair with variable results.  Jouve et al. 
implanted allogenic growth plate chondrocytes in type I collagen gel into rabbit growth 
plate defects [48].  The implanted constructs remained viable after six weeks, produced a 
proteoglycan rich extracellular matrix, and began to display a columnar cellular 
organization similar to the surrounding growth plate tissue.  However, neither prevention 
of bone bridge formation nor growth restoration was demonstrated.  In an ovine model, 
Foster et al. also studied transplantation of allogenic growth plate chondrocytes into 
growth plate defects [49].  Isolated chondrocytes were cultured at high density until 
constructs containing a cartilaginous matrix were produced.  Chondrocyte columniation 
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and endochondral ossification were observed 8-12 weeks post-implantation and 
reformation of a bone bridge was prevented.  However, cell survival was highly variable 
perhaps due to a consistent local immune response to the implants and growth restoration 
was not demonstrated.  In another rabbit model, Zhou et al. found that growth plate 
chondrocytes cultured on polylactic acid scaffolds to produce an engineered growth plate 
prevented bone bridge formation and partially restored growth [50].   
More recently, models that employ the implantation of chondrogenic stem cells 
have emerged.  Hui et al. found that fibrin alone resulted in the formation of a bone 
bridge and higher limb length discrepancies compared to mesenchymal cells seeded in 
fibrin in a rabbit model of growth plate injury [51].  Chen et al. reported that agarose 
alone did not inhibit angular deformity or premature fusion [52].  In both cases, the 
inclusion of MSCs into the gels rescued growth function.  Both studies demonstrated the 
reformation of a growth plate histologically, however, no data was provided to 
demonstrated integration of the regenerated growth plate with the native tissue or if the 
growth rate of the implant tissue matches that of the native region [51, 52].  Additionally, 
delivery of MSCs alone did not inhibit bone bridge formation or regenerate the growth 
plate [53].   
Several small animal studies of growth plate injury have also been reported.  In a 
5 week old Sprague Dawley rat model, Garces et al. found that a 1 mm defect drilled into 
the growth plate from the surface of the femur resulted in no significant differences in 
length or growth-plate height between injured bones and their controls.  Defects were 
filled by a bone bridge that grew wider as time passed after the surgical procedure [54].  
In a murine model, Lee et al. demonstrated that the growth plate defect healing begins 
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with fibrous tissue deposition followed by infiltration of mesenchymal cells and, finally, 
bone bridge formation from the rim of the defect inward [25].  This time-course of tissue 
infiltration was also observed in a tibial model of centralized defects developed by Xian 
et al. in rats [21].  Both authors also showed that bone bridge formation within the growth 
plate defect occurred through the intramembraneous pathway [21, 25].  To further 
characterize this process, Xian et al. have also examined the time-course of inflammatory 
cytokine expression, chondrogenesis, and endochondral ossification, within the injured 
growth plate using gene expression and immunohistological means [55-57].   
Rats have been widely used to study endochondral ossification in the fracture 
callus [58, 59], as a model for osteoporosis [59, 60] and arthritis [19], and to study the 
effects of irradiation and systemic diseases on growth plate morphology [17, 18, 61].  
Therefore, a wealth of information exists about the effects of various disruptive models 
on growth plate biochemistry and many antibodies and primer sequences have been 
developed.  In fact, recent studies of the rat genome have shown that rodents are closer to 
humans than cats, pigs, or zebrafish [62].  The rats’ small size also make them ideal for 
the quantitative characterization of the physical effects of growth plate injury using the 
micro-CT.   
 
Cartilage Tissue Engineering 
  
As demonstrated in previous animal models, cartilage tissue engineering is an 
attractive option for the treatment of growth plate defects [48, 50-52].  From decades of 
articular cartilage tissue engineering studies, a wealth of information has emerged about 
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chondrocyte response to environmental cues in vitro in numerous scaffold types.  
Unfortunately, the limited sources for primary chondrocyte isolation and their well 
characterized expansion limitations make this cell type an unlikely candidate for tissue 
engineering applications [63-65].  Mesenchymal progenitor cells offer an alternative cell 
resource with nearly unlimited expansion potential capable of supplying large quantities 
of cells.  However, the success of any tissue engineered construct requires the correct 
marriage of scaffolds, growth factors, and cells for optimal matrix production and 
integration into the defect site. 
 
Scaffolds 
   
 In tissue engineering, the criteria for scaffold design, in general, is that the 
material must exhibit biocompatibility and be biodegradable, provide mechanical support 
during the healing process while degrading to match tissue replacement, maintain the cell 
phenotype, and support deposition of matrix [66, 67].  When addressing biocompatibility, 
consideration must be given to not only how the recipient tissue will respond to the intact 
scaffold, but also to its degradation products as the tissue regenerates [66, 68, 69].   
Several types of biodegradable scaffolds are being investigated by articular 
cartilage tissue-engineering researchers.  These include woven scaffolds like polyglycolic 
acid (PGA) and polylactic acid (PLA), gels made from natural proteins like collagen, 
fibrin, chitosan, agarose, and alginate, and natural scaffolds (autologous or allogenic 
tissues) [66, 68, 70].   
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Materials derived from polyhydroxyacids are attractive because they have been 
approved by the US Food and Drug Administration (FDA) for application in vivo for 
many years [66, 68-70].  Polyglycolic acid (PGA) and polyL-lactic acid (PLLA) are 
easily extruded and have been well studied for cartilage applications [66].  They support 
cell attachment and matrix production of several different cell types involved in 
osteochondral tissue engineering [66, 69].  They have been shown to support significant 
matrix accumulation by young bovine chondrocytes in a rotating wall and perfusion 
bioreactors in vitro [71, 72], however, the results from several animal models is variable.  
[66, 68].  Although the viscoelastic properties of neocartilage developed on these meshes 
tends to approach that of some native cartilages, they are not likely to withstand 
physiological load or integrate with native tissues [66].   
The recovery of the chondrocytic phenotype in hydrogels such as alginate and 
agarose has also been well characterized [73-79].  In these matrices, chondrocytes that 
have dedifferentiated due to monolayer expansion are induced to re-express cartilaginous 
matrix molecules [63, 64, 80].  The cross-linked network of hydrogels mimics the natural 
extracellular matrix and the high water content of hydrogels facilitates the exchange of 
nutrients and gases [81].  Hydrogels are also attractive because their high hydration 
provides the construct with initial mechanical stability and allows diffusion of nutrients 
and waste products to and from the encapsulated cells [82].  The ability of these gels to 
be injected into a defect site and polymerized in situ make hydrogels ideal for easy 
delivery clinically and molding into any shape [83].  Gels containing collagens and 
proteoglycans are the most popular natural scaffolds using in orthopaedic tissue 
engineering research based on numerous studies demonstrating the ability of these matrix 
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proteins to enhance chondrocyte function [69, 84-88].  However, the mechanical fragility 
of these scaffolds limits their usefulness in load bearing applications [83]. 
Recent studies have demonstrated that another US FDA approved polymer, 
photopolymerizable polyethylene glycol-based (PEG) hydrogels [66], support 
chondrogenesis and constructs up to 8mm in thickness can be produced [89-95].  The 
degradation rates and initial mechanical properties can be distinctly controlled and 
scaffolds with specific microarchitectures (i.e. multilayered stratified constructs) can be 
created using this system.  These properties are attractive for the development of tissue-
engineered constructs that recapitulates the complex microarchitecture of cartilaginous 
tissues [69, 96].  
Natural scaffolds such as periosteum and osteochondral grafts derived from both 
autographic and allogenic sources have been used in the clinical setting for years to repair 
cartilaginous defects [68, 97, 98].  The cells of the inner layer of periosteal tissue, called 
the cambium, have been shown to be able to undergo chondrogenesis in vitro [99-102].  
In combination with the osteogenic outer layer, the periosteum is an attractive scaffold 




Many of the factors that direct cartilage matrix synthesis also regulate the process 
of chondrogenesis [5, 103]. Therefore, understanding the roles of specific signaling 
molecules in the growth plate may aid in controlling the phenotype of cells in tissue-
engineering applications developed in vitro prior to in vivo implantation.  The phenotype 
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of chondrocytes in the growth plate is tightly regulated by interactions between autocrine 
and paracrine factors secreted by chondrocytes and cells from the surrounding tissues 
[103].  Numerous investigators are currently conducting in vitro studies to elucidate the 
effects of growth factors [5, 103-107], glucocorticoids [108-110], steroid hormones [111, 
112], and matrix molecules on growth plate chondrocytes [113].  Ballock et al. showed 
that growth plate cells will spontaneously form a growth plate-like tissue including a 
columnar arrangement of flattened proliferating cells and hypertrophic cells in vitro 
[114].  It has also been shown that BMP-2, 4, and 7 are capable of inducing hypertrophy 
[6], while TGF-β1 has been shown to inhibit hypertrophy in growth plate cells placed in 
aggregate culture [114, 115].  The addition of exogenous PTHrP to growth plate cultures 
increases expression of MMP-3 and 9 [116] and inhibits hypertrophy, possibly through 
genomic regulation of Ihh expression [117, 118].  The response of growth plate cells have 
also been shown to be dependent on maturation state [119].  Over the years, Boyan and 
colleagues have increased our understanding of the role of vitamin D3 metabolites in the 
regulation of endochondral ossification and regulation of the growth plate phenotype.  
They have demonstrated the maturation-dependent response of growth plate cells to 
1α,25-(OH)2D3 and 24R,25-(OH)2D3 as well as the intercellular mechanisms of their 
response to PTH, TGF-β1, and BMP-2 [120, 121].  The numerous studies in this area on 
the response of chondrogenic cells to in vitro culture conditions aids in the selection of 
environments in which the desired cell phenotype can be regulated, which will, in turn, 
determine how cells implanted into a growth plate defect respond to the complex 






 While primary growth plate cells from mice, rat, and chick have been studied in 
vivo to further understand development and examine the effects of various growth factors 
on the maturation cycle of chondrocytes, little work has been done to investigate the 
applicability of these cells for cartilage tissue engineering.  In studies comparing 
chondrocytes from different sources, growth plate cells exhibited the ability to secrete a 
cartilaginous matrix in vitro and in vivo [122, 123].  Bentley et al. compared the ability of 
allogenic epiphyseal and articular derived chondrocytes to heal a full thickness 
osteochondral defect in rabbits.  The authors found that epiphyseal chondrocytes 
exhibited superior filling of the defect and integration into the surrounding tissue over 
articular chondrocytes.  While articular-derived cells did secrete a metachromatic matrix 
that stained intensely for sGAGs, the resulting tissue was surrounded by fibrous tissue 
and immune cells [122].  In another study comparing porcine auricular, articular, 
costochondral derived cells seeded in a fibrin matrix, Xu et al. found that all of the cell 
types secreted similar matrices high in sGAG content.  However, constructs containing 
costochondral cells maintained their original shape better than auricular chondrocytes, 
which overgrew, and articular chondrocytes, which significantly shrank over time.  
Additionally, costochondral and auricular constructs had superior biomechanical 
properties to those made with articular chondrocytes [123].   
Clinically, epiphyseal chondrocytes are introduced into a growth plate defect 
through whole physeal transfer, and animal studies have shown that this process is 
superior to fat interposition at preventing bar bridge formation and angular deformities 
 
19 
[124, 125].  However, studies have also shown that the cells of inserted epiphysis does 
not respond to the biochemical feedback loop that regulates chondrocyte maturation and, 
therefore, the rate of growth of the graft may not match the host site [42, 43, 45, 46].  In a 
study in rabbits by Abad et al., the authors found that if the epiphysis was inserted upside 
down, the cells graft continued to undergo endochondral ossification in the same 
direction and did not integrate with the surrounding tissue [126].   
The feasibility of implanting isolated epiphyseal cells into growth plate defects 
also requires more investigation.  A study by Lee et al. showed that chondrocytes isolated 
from the resting zone of rib cartilage and cultured in pellet culture for 14 days secreted a 
cartilaginous matrix and exhibited growth plate morphology.  When implanted into a 
growth plate defect, graft growth and endochondral ossification continued.  However, the 
ability of these constructs to prevent limb shortening or angular deformities was not 
investigated [127].  Therefore, it is unknown whether a growth plate graft created in vitro 
will adapt to the local biochemistry of the host growth plate any better than an autologous 
whole physeal transfer.  In animal models that did investigate these parameters, the 
treatment did not completely prevent bone bar formation or correct angular deformities 
[48, 49] 
Despite the superior matrix production and integration reported with tissue 
engineered constructs using growth plate chondrocytes in vivo, the use of these cells 
clinically is limited by lack of significant sources for cell isolation, the donor site 
morbidity associated with that harvest, and limited ability for expansion in vitro [126].   
When autologous cartilage tissue or cells are used in the repair process, it is often 
difficult to harvest a large number of chondrocytes without causing substantial additional 
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damage due to donor site morbidity [115, 128].  Ample cell numbers may be obtained 
through in vitro monolayer expansion, or passaging, of the desired cells.  Unfortunately, 
passaging causes chondrocytes to dedifferentiate, a condition marked by decreased 
expression of two necessary cartilage matrix components: type II collagen and sulfated 
glycosaminoglycans (sGAGs), as well as increased expression of undesirable type I 
collagen [63-65, 129].  Therefore 3D culture techniques have been developed in 
scaffolds, including gels and polymers, that maintain their rounded morphology and 
stabilize their phenotype [67]. 
Numerous methods have been investigated to modulate the phenotype of articular 
chondrocytes in vitro.  It is well recognized that dynamic seeding and culture of 
chondrocytes yields constructs with superior matrix content and biomechanical properties 
compared to static culture [67, 130] and it is likely that bioreactor technologies will close 
the gap between research and clinical application of tissue engineering strategies to 
cartilage injury [115].  Studies have also focused on the TGF-β, FGF, and IGF families of 
growth factors for modulation of chondrocyte behavior in vitro [115].  Despite the 
advances made so far in tissue-engineering application for cartilage repair, the zonal 
variation of cartilaginous tissues has not been mimicked and in vivo applications of 
articular cartilage cells involve delivery of a homogeneous distribution of a 
heterogeneous population of articular cartilage surface, middle, and deep cells [67].   
The results of treatment of growth plate defects in animal models with articular 
cartilage cells has been variable.  When these cells were delivered to an injury that 
involved 66% of the growth plate in collagen gels, angular deformation was reduced 
compared to fat grafts, but bone still formed between the construct and native tissue 
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[131].  Lee et al. delivered chondrocytes in agarose to treat an injury involving 50% of 
the growth plate in a murine model.  The authors found that the implanted cells 
contributed to the formation of a functional growth plate with some residual angular 
deformity [25]. 
Adult stem cells have harvested from a variety of tissues including trabecular 
bone, muscle, fat, synovium, amniotic fluid, placenta, umbilical cord, and bone marrow 
[132-143].  Each cell type exhibits different phenotypical behavior in vitro depending on 
the extraction, expansion, and differentiation methods used by the investigator.  In 
general, stem cells have higher expansive abilities than primary cells in vitro and can be 
differentiated into the chondral, osseous, and adipogenic phenotypes [144].  There is 
overlap of cell surface markers of the adult stem cells from different tissues, but no 
criteria has been elucidated that defines a stem cell [83].  Of the adult stem cell types, 
bone marrow derived stem cells (BMSCs) have been the most studied for orthopaedic 
applications [83].  In a study comparing the multipotential capabilities of marrow- and 
adipose-derived stem cells, Liu et al.  found that BMSCs may be a better choice for 
cartilage and bone tissue engineering than adipose-derived cells [145]. 
The clonal nature of BMSCs was first revealed in the 1960’s [146].  The bone 
forming properties of rat BMSCs was later reported by Friedenstein [147].  Since then, 
the multipotential ability of these cells has been demonstrated [148-150].  Marrow-
derived progenitor cells from several species including rabbit, goat, canine, bovine, and 
human can be induced to differentiate along the chondrogenic lineage in vitro and in vivo 
[151-155].  The chondrogenic potential of stem cells have been found to be associated 
with expression of CD105, a TGF-β receptor [83, 156] and members of the TGF-β 
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family, particularly TGF-β1, have been shown to promote chondrogenic differentiation in 
a variety of species [157, 158].   
BMSCs make up 0.001-0.01% of nucleated cells in the bone marrow and 
therefore require in vitro expansion [83].   As with primary chondrocytes, extensive 
passaging of BMSCs has been shown to decrease the ability of cells to produce a 
functional matrix under differentiating conditions [63-65].  Tsutsumi et al. examined the 
effects of passaging on the ability of bone marrow stromal cells to differentiate down the 
mesenchymal pathway and found that treating the cells with 1 ng/ml of FGF-2 during 
monolayer expansion increases the rate of cell division, abrogates the negative effects of 
passaging, and enhances differentiation [148].  Hanada et al. also showed that FGF-2 
increased BMSC osteogenesis [159] and numerous studies have shown FGF-2 to be 
mitogenic for many different cell types [158, 160-162].  These studies demonstrate that 
FGF-2 positively affects BMSC mitogenesis and differentiation. 
In recent studies where stem cells have been used to treat growth plate defects, 
investigators found that the delivery of MSCs into the gel systems rescued growth 
function.  These studies demonstrated the reformation of a growth plate histologically, 
[51, 52].  It has also been reported that a delivery vehicle for the MSCs was required to 




Damage to the growth plate due to injury, disease, or surgical intervention may 
lead to limb length discrepancies due to premature fusion of whole or part of the physis.  
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These deformities not only impair the function of the individual as they grow, but may 
lead to future orthopaedic problems or injuries resulting from abnormal loading of the 
affected joints.  Once the growth plate is fused, these conditions may only be corrected 
with expensive and painful procedures such as distraction osteogenesis and, in extreme 
cases, total joint replacement.  Therefore it critical to treat these defects while the patient 
is still growing.  While previous studies of growth plate defects in animal models have 
demonstrated that stem cells inserted into growth plate defects can reduce or correct 
angular deformity and limb length discrepancy, few studies have examined correction of 
a centralized defect.  Furthermore, to our knowledge, no one has performed a detailed 
analysis on the relationship of changes growth plate morphology to subsequent length 
discrepancies.  Therefore, the overall objective of this research project is to quantitatively 
evaluate the application of tissue engineering methods to the treatment of growth plate 
defects in a small animal model.  Combining clinically relevant tissue engineering 
techniques and materials, the interdependence of monolayer expansion, hydrogel culture, 
and growth factor regimen on rat BMSC chondrogenesis was studied.  A method was 
then developed to deliver chondrogenic progenitor cells to the injured growth plate.  
Using micro-CT imaging, growth plate morphological parameters were quantitatively 
assessed and correlated with whole bone growth kinetics during natural healing and with 
surgical intervention.  This research is significant because it: 1) presents novel techniques 
with which the alterations to growth plate morphology due to injury and treatment may 
be quantitatively evaluated and 2) enhances our understanding of the factors that 






CHARACTERIZATION OF A SMALL ANIMAL GROWTH PLATE 




The growth plate is the cartilaginous region at the ends of long bones responsible 
for their longitudinal growth.  Approximately 42% of male children and 27% of female 
children experience a broken bone by the age of 16 and it is estimated that 15-20% of 
these fractures will involve the growth plate [12, 13, 163].  Growth plate cartilage is 
biomechanically weaker than articular cartilage and has limited ability for self repair 
[13].  Therefore, fractures involving epiphyseal cartilage may result in an angular 
deformity if the injury occurs within the peripheral regions of the tissue an in a limb 
length discrepancy if the defect is centrally located [15, 164].  In addition to damage 
during fracture, injury to the growth plate may also result from the removal of 
osteosarcomas, the treatment of bone cysts, diabetes, chemotherapy, juvenile arthritis, 
and limb stabilization in the case of osteopetrosis imperfecta [17-20].  Abnormal loading 
due to these joint incongruities may have life-long consequences [16]. 
 The growth plate consists of five zones – the resting cell zone, proliferative cell 
zone, pre-hypertrophic cell zone, hypertrophic cell zone, and calcified cartilage.  Each 
zone consists of chondrocytes at different stages along the endochondral differentiation 
pathway.  The maturation states of these cells are controlled by growth factors in a 
feedback loop that includes parathyroid hormone related protein (PTHrP), transforming 
growth factor-β (TGF−β), and Indian hedgehog (Ihh) in a process called endochondral 
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ossification.  At terminal maturation, hypertrophic chondrocytes calcify the extracellular 
matrix and undergo apoptosis, leaving behind a mineralized scaffold for new bone 
formation.  Terminal chondrocytes also secrete factors that stimulate blood vessel 
infiltration and regulate osteoblastic activity [165].   
Acute injuries that traverse the growth plate (Salter types III and IV) typically 
result in the formation of one or more bone bridges that are visible on radiomicrographs 
and MRI images [27, 28].  These bridges may extend from the epiphysis to the 
metaphysis [1].  The most common treatment of minor growth plate injuries – those 
where the bone bridge size is <40% of the growth plate and the prospective growth 
period is at least 2 years – is the Langenskiöld procedure [1, 15].  It involves removal of 
the bone bridge and insertion of autologous fat into the empty space to prevent the bone 
bridge from reforming.  This procedure is labor intensive and, despite standardization of 
the technique in the field, clinical success is unpredictable, ranging from 15-38% [1].  
This variability may be the result of the propensity of fat to support bone formation after 
bleeding at the graft surface, fibrous degeneration and shrinking, dislocation of the graft, 
or necrosis in the center of the graft [1, 38, 39].   
An alternative method, microsurgically revascularized epiphyseal plate transfer, is 
used to treat severe deformities.  Here, a section of autologous growth plate and a flap of 
skin is transferred from another anatomical site to the injured area and the vasculature 
from the skin are anastamosed to major blood vessels in the surrounding recipient site 
[42, 43].  This procedure restores growth function to the growth plate by ensuring 
adequate blood flow to the area, a requirement for proper endochondral ossification.  
However, the procedure continues to be limited because it is very complex and labor 
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intensive, the growth rate of the epiphysis is site dependent [44], donor site morbidity is 
prevalent [42, 44], and transplanted growth plates may not adapt easily to the recipient 
site [42, 43, 45, 46].  Therefore, limb discrepancies or angular deformities may still occur 
and distraction osteogenesis following skeletal maturity may be indicated [44]. 
One of the major obstacles to growth plate injury treatment is assessing the 
morphology of the injured space.  Radiographs are the first mode of analysis in the clinic, 
but images are difficult to interpret and not all bridges will be visible [27, 28].  MRI 
analysis with fat-suppressed three-dimensional (3D) spoiled gradient-recalled echo has 
superior diagnostic capabilities over radiographs [27, 29-32].  Unfortunately, clinicians 
may have to wait up to 8 months before a bone bridge is apparent in a MRI image [35].  
It was also noted that some coronal and sagittal images of the normal knee show 
discontinuity of the physeal cartilage (drop-out sign), which may be mistaken for 
premature closure [33].  Due to these limitations, growth plate defect healing in animal 
models is typically defined as a restoration of whole bone growth or lessening of angular 
deformity on radiographs, and the changes to overall growth plate morphology are 
typically characterized using histomorphometric methods that may damage the local 
microarchitecture. 
Microcomputed tomography (micro-CT) scans have been shown to improve 
accuracy of screw insertion clinically to fix epiphyseal fractures [36].  Using CT scans,  
3D reconstructions of human limbs have also allowed detailed analysis of the epiphysis 
and femoral neck for treatment of a slipped capital femoral epiphysis [37].  These 
observations suggest that CT scans would allow clinicians to more accurately assess 
defect placement, treatment options, and changes in growth plate morphology over time.   
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Using 3D reconstructions from micro-CT images of rat tibiae,  Martin et al. [166] 
have demonstrated that, as rats age, the natural process of growth plate closure is marked 
by an accumulation of mineralized struts or tethers that traverse the growth plate.  These 
tethers form perpendicular to the plane of the growth plate, connecting the epiphyseal and 
metaphyseal bone surfaces.  Tether formation has been noted on histological sections of 
fusing dog, pig, and human epiphyses [167].  Though the rat growth plate never fully 
fuses, the growth plate gets thinner and the number and volume of these tethers increases 
with time.  In their report, Martin et al. were able to quantify both the number and 
volume of these tethers through micro-CT analysis [166]. 
Several animal models of growth plate injuries have been developed to test 
clinical approaches to diagnosis and repair of the growth plate.  These include rabbit [40, 
48, 50], sheep [49, 168], mice [25], and rats [21, 54, 169].  Using these models, the 
effects of numerous growth factors and insertion materials have been assessed with 
variable results.  Alternate filler materials have included frozen hyaline cartilage, iliac 
apophysis, and nonbiologic materials such as methylmethacrylate, bone wax, and silastic 
[38, 40, 48].  Although cartilage is reported to be more effective than fat in preventing 
growth retardation and angular deformity, none of the aforementioned materials prevents 
reformation of the bone bar or restores function to the growth plate [39, 41].   
The overall goal of this study was to demonstrate the utility of micro-CT as a non-
invasive imaging modality for assessing growth plate injury and repair.  Therefore, the 
first aim of this study was to establish a surgical defect model of growth plate injury in 
the distal femur of adolescent rats and characterize the changes in growth plate and bone 
lengths due to the presence of a centralized defect in the distal femur of adolescent 
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Sprague Dawley rats.  Using micro-CT images, healing was determined by quantitatively 
monitoring bone bridge formation into the defect area as well as changes in growth plate 
thickness, volume, and natural closure dynamics (tether formation).    Additionally, we 
hypothesize that the inhibition of bone bridge formation within the defects is required to 
prevent growth retardation and that prevention requires a scaffold that will completely 
occlude the defect.  Therefore, the second aim of this study was to characterize the 
response of growth plate healing to injection of an in situ gelling agarose within the 
centrally localized defect.   
 
Materials and Methods 
 
Surgical Procedure 
All procedures were performed under Georgia Institute of Technology IACUC 
approved guidelines.  Sprague Dawley male rats (body weight 100-125 grams, 
approximately 5 weeks old) (Charles Rivers Laboratory, Wilmington, MA) were used in 
all studies.  Animals were anesthetized using 5% isoflurane and prophylactic antibiotics 
were administered by subcutaneous injection.  The skin over both knees sterilely prepared 
and draped, providing a sterile surgical field.  A 2 cm midline incision was made on the 
anterior aspect of the right knee joint and a medial parapatellar arthrotomy performed.  
The patella was dislocated laterally to expose the trochlear groove of the distal femur.  
Using a hand drill, a central defect was created across the physes of the distal femur by 
drilling through the articular cartilage between the condyles, normal to the cross-sectional 
plane of the bone shaft, and then further up the intramedullary canal (Figure 3.1).  
 
29 
Preliminary micro-CT analysis of five-week-old limbs showed that the distance from the 
cartilage between the condyles to the growth plate is  approximately 4 mm.  Therefore, 
the depth of drilling into the metaphyses was controlled with a mechanical stop so that 
the defect did not enter the marrow cavity. The defect was then irrigated with a sterile 
saline solution.  The patella was relocated to its original position and the medial joint 
capsule was closed with 4-0 vicryl suture.  The skin was closed using wound clips and 
the surgical area was washed with hydrogen peroxide.  The wound clips were removed 
10-14 days post surgery.  The left leg was left unoperated and used as the control for all 
analyses.  In the first study, animals were euthanized by CO2 asphixiation on days 28 
(n=5), 56 (n=8), and 112 (n=5) post surgery to determine the timecourse of defect 
healing.  In the second study, in addition to empty defects (n=4), defects were filled with 
a 1% solution of in situ gelling SeaKem GTG agarose (Cambrex, Rockland, ME) (n=6).  




Figure 3.1.  Growth plate surgical defect 
Appearance of distal femur after growth plate defect created (left).  Image demonstrating 
defect placement and depth (right). 
 
 
    Defect 







The epiphyseal region of the defect legs were scanned at a 20 µm voxel size on a 
VivaCT 40 system (Scanco Medical, Bassersdorf, Switzerland).  The volume of bone 
infiltration into the defect (bone bridge formation) was measured by isolating a 2 mm x 
15 slice (0.32 mm) cylindrical region within the original defect contained entirely within 
the growth plate as shown in Figure 3.2A.  This parameter was termed the defect bone 
volume fraction.  To quantify the effect of the defect on growth, whole femurs from the 
defect and contralateral control legs were scanned at a voxel size of 36 µm and the 
lengths of the whole bone and diaphysis of each femur were measured from the rendered 
3D images.  The diaphyseal length was defined as the distance from the lesser trochanter 
to the metaphyseal plate and the total length was defined as the distance from the greater 
trochanter to the edge of the femoral condyles (Figure 3.B).  Finally, the growth plate 
was isolated from the surrounding bone tissue in the micro-CT images by manual 
contouring of 2D slices of sagittal images.  The contoured regions were compiled to 







   
 
Figure 3.2.  Micro-CT Analysis. 
Images demonstrating (A) the method of determining the mineral content within the 
original defect.  A controlled volume was used for each sample.  (B) The diaphyseal and 
overall lengths of the contralateral and defect bones.  (C) The location, position and 
morphology of the epiphyseal growth plate within the distal end of the femur.  Note the 
four ridges that are located along the edges of the femoral-patellar groove. 
 
 
 In order to most accurately characterize the changes in growth plate morphology, 
the contoured areas were further analyzed to ensure that mineralized regions of bone and 
cartilage were removed.  To achieve this, the contour areas of 2D images were decreased 
pixel by pixel (peeled) from the surface until an accurate representation of the growth 
plate was attained.  From these images, total growth plate volume was calculated and 
thickness maps generated.  Thickness measurements were obtained by expanding spheres 
at distinct voxels within the 3D volume.  Total volume was determined by counting the 
number of voxels within the contoured region and multiplying the value by the voxel 
volume.  To determine the effect of the defect on the natural course of growth plate 
closure in Sprague Dawley rats, the volume of mineralized tethers within the growth plate 















Whole femurs were fixed in 10% neutral buffered formalin at 4°C for 1 week and 
stored in 70% ethanol at 4°C until histologic processing.  Samples were then decalcified 
in a 22% formic acid solution buffered with 10% sodium citrate and then embedded in 
paraffin.  Four micron sections were taken through the cross-section and stained with 
haematoxylin and eosin (H+E).   
 
Statistics 
The effects of treatment on group means were assessed using the analysis of 
variance (ANOVA) general linear model.  Statistical significance (p<0.05) between 
individual group means were determined using Tukey's post hoc test for multiple 




A preliminary experiment was performed to determine how close this model 
recapitulates the physiology of a centralized growth plate defects in humans, specifically 
bone bridge formation and limb length shortening.  Animals were euthanized at 0, 7, 10, 
14, 21, 28, and 35 days (n=1-2) after surgery and both femurs removed.  There was no 
apparent difference in defect limb length compared to its contralateral control at any of 
the time points (not shown).  Bone was seen to infiltrate the defect as early as day 10 and 
BVF within the defect increased in a non-linear manner with the most dramatic effects at 
days 28 and 35 (not shown).   
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Based on these results, a time-course study was performed in which healing was 
assessed at days 28, 56, and 112 days post surgery.  At day 28, the total length of the 
contralateral control leg was higher than the defect leg.  At days 56 and 112, total and 
diaphyseal limb lengths of the defect legs were shorter than their contralateral controls 
(Figure 3.3A&B).  Overall, the defect resulted in a growth reduction of 63% between 28 
and 56 days and 90% between 56 and 112 days.  
 





















Figure 3.3.  Growth plate defect decreases limb length. 
Changes in the (A) total length and (B) diaphyseal length of the defect and contralateral 
control femurs over time as determined by micro-CT analysis.  * indicates significant 
difference from the defect leg. 
 
 
Optimization of growth plate morphological  parameters 
Figure 3.4Figure 3.A demonstrates the effects of the peel protocol for 0, 3, and 5 
pixel peels.  This method has a significant effect on the measured parameters, 
predominantly at 56 days (Figure3.4Figure 3.B).  At day 56, there was a trend indicating 





















plate volume decreased significantly as the peel number increases.  The tether BVF 
decreased drastically after the initial peel, but did not change significantly thereafter.  
Based on this analysis, all of the growth plate morphological results were obtained from 
growth plate images analyzed with a peel of three. 
 
Defect results in a thinner growth plate with increased tether volume 
Day 112 growth plates were too thin to reproducibly isolate from the surrounding 
bone tissue.  The growth plate became thinner over time and the presence of a defect 
through the tissue resulted in a significant reduction in thickness as compared to 
contralateral controls by day 56 (Figure 3.5A & Figure 3.6).  The defect BVF (bone 
bridge formation within the defect) did not increase significantly between any of the 
time-points (Figure 3.5B).  In contrast,  the tether BVF was significantly higher in the 
defect limb by day 56 (Figure 3.5C & Figure 3.6).  Histological staining of day 56 
samples confirmed bone infiltration into the defect.  In addition, the defect resulted in 
disorganization of the cellular morphology of the growth plate (Figure 3.7A).  The 
proliferative and hypertrophic zones were highly disorganized compared to their 
contralateral controls by day 56.  Formation of tethers was also confirmed by 


















Figure 3.4. Optimization of growth plate morphological parameters. 
(A) Images demonstrating the effects of the number of pixels removed from 2D contours 
(peels) on the representation of growth plate thickness, BVF, and total volume. The 
number below the image indications the number of pixels removed from the outside 
edges of the contours used to generate the image. The circled region is a mineralized 
tether that disappears as the peel number increases.  (B) The effects of the different peels 
on the quantitative estimate of growth plate morphological parameters.  * indicates 











































































































Figure 3.5.  Growth plate morphology.   
 
Morphological changes in the defect and contralateral control growth plates over time as 
determined by micro-CT analysis.  (A) Change in average thickness of the growth plate 
over time.  (B) Defect Volume Fraction – Infiltration of bone into the original defect site 
(bone bridge).  (C) Tether Volume Fraction – Volume of mineralized tether formation 
through the growth plate outside of the centralized defect region as an indication of the 
degree of closure over time.  * indicates significant difference from the defect leg. 
 
`                               
Figure 3.6.  Growth plate thickness maps.   
Growth plate thickness maps of defects and contralateral controls at 28 and 56 days.  
Images were generated by compiling 2D contours into 3D images.  The defect region was 
not included in the contours.  The white regions within the maps outside the large 
centralized defect area indicate the location  of mineralized tissue (tether) formation 
through growth plate.  Note the difference in the scale bars for the thickness maps at 28 
and 56 days.   
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Figure 3.7.  Growth plate defect results in cellular disorganization within the growth 
plate.   
 
(A) Histological analysis of 56 day samples confirmed bone infiltration into the defect.  
Insets show the growth plate at higher magnification.  Note the loss of proliferative cell 
columns (white arrowheads) and hypertrophic cells (black arrowheads).  (B) Mineralized 
tethers formed through the growth plate connecting the epiphyseal and metaphyseal bone 
(arrow heads).  Scale bar = 400µm on entire epiphysis images.   Scale bar = 50µm on 

















Positive correlations between whole bone and growth plate morphological parameters 
To assess whether the limb length was a significant predictor of the growth plate 
thickness, volume, and/or tether BVF, these parameters were expressed as the percent 
difference between the defect and control legs.  We found that total limb length was 
positively correlated in a non-linear fashion with the growth plate thickness (R2=0.88; 
Figure 3.8A) and with the tether BVF (R2=0.78; Figure 3.8B).  The growth plate volume 
was directly correlated to growth plate thickness (R2=0.96; Figure 3.8C) and the percent 
difference in growth plate volume was positively correlated to the percent difference in 
limb length (R2=0.61; Figure 3.8D). 
 
Injection of an in situ gelling  agarose decreases limb length discrepancy  
At day 56, gel insertion had a significant effect on growth plate defect healing.  In 
both the gel filled and empty groups, the defect legs were significantly shorter than 
control legs (Figure 3.9A).  However, the defects filled with agarose were significantly 
longer then their empty counterparts.  This resulted in a decrease in limb length 
discrepancies from 9.74±0.86% in the empty defect to 5.02±1.19% in those defects filled 
with agarose for 56 days (not shown; p=0.02).  The defect growth plates were thinner 
than the contralateral control limbs in all cases (Figure 3.9B).  However, there was also a 
trend toward increased average growth plate thickness of the agarose treated defects 
compared to those defects left empty (p=0.07).  The tether BVF was higher in defect legs 
(Figure 3.Figure 3.9C) and there was no difference between empty and agarose treated 
groups.  The defect BVF was the same with or without agarose (not shown).  Histological 
analysis of the defect region showed the presence of agarose remnants with little cellular 
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infiltration and some regions of mineralization, but no evidence of growth plate 
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Figure 3.8.  Positive correlations between whole bone and growth plate morphological 
parameters.   
Correlations between the % difference in total length and (A) % difference in growth 
plate thickness legs and (B) % difference in tether bone volume fraction. Correlations 
between the growth plate volume and (C) the average growth plate thickness and (D) the 






























































Figure 3.9.  In situ gelling  agarose decreases limb length discrepancy. 
Whole bone and growth plate morphological parameters after 56 days.  Defects were 
either left empty or filled with 1% agarose.  (A) total length, (B) average growth plate 
thickness, (C) tether BVF, and (D) H+E stain of an agarose treated defect.  * indicates 
significant difference from the defect leg; ‡ indicates difference of agarose filled defects 
from the empty defect leg.  Black arrows indicate islands of agarose gel surrounded by 





 In this study, a small animal model of growth plate injury was developed and 
characterized using microcomputed tomography and basic histology.  Specifically, we 
were able to quantify the time-course of bone formation within the defect, changes in the 







closure dynamics of the rat growth plate by measuring the formation of mineralized 
tethers throughout the tissue.  We have demonstrated that limb length was significantly 
reduced when the defect was left empty for 28 days.  After 56 days, the average growth 
plate thickness was significantly decreased and the degree of growth plate fusion as 
measured by mineralized tether formation was increased.  We also found that limb length 
is correlated with growth plate thickness, volume, and degree of tether formations.  
Overall these parameters can be used to establish the severity of the injury and aid in 
developing treatment options.  
This model replicates the major features of a growth plate injury that traverses the 
tissue – formation of a bone bridge and limb length discrepancies – that is comparable to 
results found in other rodent models investigating the molecular mechanisms of bone 
bridge formation [21, 25, 55-57].  In a murine model, Lee et al. demonstrated that the 
defect begins with fibrous tissue deposition with infiltration of mesenchymal cells and 
that the bone bridge forms from the rim of the defect inward [25].  This time-course of 
tissue infiltration was also observed in a tibial model of centralized defects developed by 
Xian et al. using a rat model [21].  Both authors also showed that bone bridge formation 
within the growth plate defect occurred through the intramembraneous pathway [21, 25].  
To further characterize this process, Xian et al. have also examined the time-course of 
inflammatory cytokine expression, chondrogenesis, and endochondral ossification, within 
the injured growth plate using gene expression and immunohistological means [55-57].  
However these time-course studies were only qualitatively characterized using 
histological techniques [21].  In the current study, we were able to quantitatively monitor 
the changes in growth plate morphology over time.  In the future, the marriage of 
 
42 
molecular and morphological models will be required to thoroughly investigate 
therapeutic options for growth plate injury. 
Previous studies performed in our lab indicate that, in empty defects, limb length 
is positively correlated with the bone volume fraction of the bone bridge and not 
negatively as expected (unpublished data).  Additionally,  there was no significant 
difference in the amount of bone formed in the defect between empty and agarose filled 
samples after 56 days even though the injection of agarose into the defect reduced limb 
length discrepancy by ~50% after 56 days.  The results of this study suggest that the 
mechanisms contributing to the observed limb length shortening was likely the observed 
cellular disorganization of the growth plate rather than formation of the bone bridge.  
Histological analysis showed thinner, more disorganized resting and hypertrophic zones.  
These zones are the predominant mechanism of growth within long bones, with the rate 
of growth determined by cell proliferation and the final intracellular volume of the 
hypertrophic chondrocytes [165].  This hypothesis is supported by several studies 
demonstrating that disorganization of the growth plate due to injury, chemotherapy, or 
irradiation is linked to limb shortening [17, 61, 164].  In a histomorphometric study in 
Sprague Dawley rats, Damron et al. showed that a single dose of gamma radiation to the 
proximal tibia resulted in a marked loss in growth rate due to rampant cellular 
disorganization and loss of reproductive potential of cells in the proliferative zone [17].  
Xian et al. demonstrated that a single dose of 5-FU, a chemotherapy agent used in both 
children and adults, resulted in decreased proliferation of chondrocytes after 2 days.  
Although the activity and organization of the growth plate returned to normal after 10 
days, there was considerable reduction in the overall length of the bone [164].  We also 
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found that increased limb length discrepancies was highly correlated to the volume of 
mineralized tether formation throughout the growth plate.  However, further investigation 
is required to determine whether this tether formation is independent of the 
disorganization of growth plate cells. 
Therapeutic strategies that are being investigated for the treatment of growth plate 
injuries include utilizing articular chondrocytes, growth plate cells, mesenchymal stem 
cells derived from different sources, and the addition of growth factors.  Unfortunately, 
none have provided complete restoration of growth plate function [48-50, 52, 53, 163, 
168-170].  When 1% agarose was used to treat the defect in our model, the limb length 
discrepancy between the defect and its contralateral control leg was decreased by almost 
50% and the growth plate was 22% thicker on average compared to defects left empty for 
56 days.  Despite these positive effects, there was no evidence of regeneration of a 
functioning growth plate within the 56 day period in either group.  Similar results were 
seen tissue by Hui et al. who found that fibrin alone resulted in the formation of a bone 
bridge and higher limb length discrepancies compared to mesenchymal cells seeded in 
fibrin in a rabbit model of growth plate injury [51].  Chen et al. also reported that agarose 
alone did not inhibit angular deformity or premature fusion [52].  In both cases, the 
inclusion of MSCs into the gels rescued growth function.  However, no data has been 
provided to demonstrated integration of the regenerated growth plate with the native 
tissue or if the growth rate of the implant tissue matches that of the native region [51, 52].  
Additionally, delivery of MSCs alone did not inhibit bone bridge formation nor 
regenerate the growth plate [53].   
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Biomolecular studies and observations from our micro-CT data suggest that bone 
formation occurs from the outer rim of the defect towards the center.  Furthermore, 
bleeding around most filler materials serve as a scaffold onto which the bone bridge still 
forms [25] (unpublished observations).  This could potentially explain why full recovery 
of growth functions has yet to be reported.  Our results combined with these studies 
suggest that a carrier is needed to act as a plug to prevent bone bar formation while 
supporting tissue formation, but then a cellular component is required to regenerate a 
functioning growth plate.  Future studies in will include the addition of a blood clotting 
agent to reduce bleeding, and hence infiltration of osteogenic factors from the marrow 
into the site.  This step will facilitate the conformation of in situ gelling agarose to the 




We have demonstrated that micro-CT images may be used to quantitatively monitor 
changes in growth plate thickness, volume, and fusion after growth plate injury in 
addition to changes in whole bone morphology.  With this model we have also shown the 
interrelationship between several growth plate morphological factors and limb length 
discrepancies.  Using these predictive parameters, CT scans may be used develop 
treatment  criteria for growth plate injury.  CT images are currently used to aide in 
surgical planning for fractures and slipped femoral epiphyses.  Methods to create 3D 
models of joints already exist, however these procedures yet to be extended towards the 





HYDROGEL EFFECTS ON BONE MARROW STROMAL CELL 




Cartilage is an avascular tissue with low cellularity and a limited capacity for self-
repair.  When cartilage is injured or has undergone degeneration, there is little cellular 
invasion into the damaged region and the intrinsic repair response is insufficient to 
completely restore the tissue to its former functional state [171].  Tissue engineering 
strategies, in which cells are seeded within a biomaterial scaffold and cultured in vitro, 
present a possible treatment option for cartilage defects.  The success of tissue-
engineered cartilage requires the correct marriage of cells, scaffolds, and growth factors 
for optimal matrix production and integration into the defect site. 
A significant challenge in cartilage tissue engineering is retrieving an adequate 
number of cells to develop the construct.  If autologous tissue or cells are used in the 
repair process, it is often difficult to harvest a large number of chondrocytes without 
causing substantial additional damage due to donor site morbidity [128].  Ample cell 
numbers may be obtained through in vitro monolayer expansion, or passaging, of the 
desired cells.  Unfortunately, passaging causes chondrocytes to dedifferentiate, a 
condition marked by decreased expression of two necessary cartilage matrix components: 
type II collagen and sulfated glycosaminoglycans (sGAGs), as well as increased 
expression of undesirable type I collagen [63-65, 129].  The identification of alternative 
cell sources and appropriate in vitro conditions to produce implantable 3D constructs that 
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effectively repair cartilage defects is therefore a high priority.  Bone marrow stromal cells 
(BMSCs) have been identified as a potential source for the treatment of musculoskeletal 
defects [95].  BMSCs are a multipotential cell population that can be stimulated to 
differentiate into cells from the mesenchymal lineage including bone, cartilage, and fat 
under specific in vitro culture conditions [148-150].    
BMSC chondrogenesis has been achieved using several types of in vitro culture 
systems, including woven polymers and hydrogel constructs, with the most popular 
system being scaffold-free (aggregate or pellet) culture [148-150, 154, 157, 172-175].  
Hydrated materials offer an attractive alternative to pellet or pre-manufactured polymer 
scaffold culture because their cross-linked network mimics the natural structure of 
extracellular matrices in vivo and their high water content facilitates the exchange of 
nutrients and gases [176, 177].  Additionally, the recovery and maintenance of the 
chondrocytic phenotype of primary articular chondrocytes in hydrogels such as alginate 
and agarose have been well characterized [75-77, 178-181].  Alginate and agarose 
solutions may also be injected and polymerized in situ, making them attractive options 
for arthroscopic repair of lesions [182].  While alginate and agarose have similar 
macroscopic properties and are sometimes used interchangebly, recent evidence suggests 
that cell-scaffold interactions result in remarkably different cell behavior in response to 
biochemical and mechanical stimulation [180, 183-185].   
Much work in recent years has focused on establishing the correct growth factor 
regimen in order to achieve chondrogenesis of BMSCs with cocktails typically including 
transforming growth factor-β1 (TGF-β1) [148, 157, 186]. Furthermore, fibroblastic 
growth factor-2 (FGF-2, also known as basic FGF) has been shown to enhance 
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mesenchymal differentiation of stromal cells at late passage numbers [148, 187] and in 
BMSCs isolated from older animals [188].  Dexamethasone, a synthetic glucocorticoid,  
has also been shown to be required for chondrogenesis of stem cells isolated from human 
bone marrow and rat calvaria [189, 190]. 
Although several different approaches have been investigated to stimulate 
BMSCs down the chondrogenic pathway [148, 149, 154, 171-173, 183, 191, 192], few 
studies have investigated the influence of scaffold material on the response of BMSCs to 
biochemical conditions that stimulate chondrogenic differentiation.  The aim of this study 
was to investigate the influence of alginate and agarose encapsulation on the 
chondrogenic response of BMSCs to FGF-2, Dex, and TGF-β1 treatment in vitro. 
 
Materials and methods 
 
Cell isolation and expansion 
Bone marrow stromal cells were retrieved using a technique previously described 
[193].  Briefly, six female 45-day old Sprague Dawley (Charles Rivers Laboratory, 
Wilmington, MA) rats were euthanized by CO2 asphyxiation and their femurs and tibiae 
removed under IACUC approved guidelines.  The epiphyses were removed from the 
proximal and distal ends of the bones using a bone cutter.  Bone marrow was flushed 
from diaphyses with α-MEM supplemented with penicillin/streptomycin 
(100U/100µg/ml; Invitrogen Carlsbad, CA) and a selected lot of fetal bovine serum 
(FBS; Hyclone, Logan, UT) using a 20 gauge needle attached to a 10 ml syringe.  The 
cell suspension was centrifuged at 1,200 RPM for 20 minutes, resuspended in media, and 
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plated at one leg/100 mm dish (Corning, Corning NY ) for 30 minutes.  Unattached cells 
were collected, replated in 150 cm2 T-flasks at a density of 150x106 cells/flask, and 
covered with 35ml of media.  Media was changed after four days to remove non-adherent 
cells.  The cells grew in circular patches that became confluent after eight days, which 
were termed primary confluence (P0).  The cells were then lifted from the surface using 
0.05% trypsin/0.53mM EDTA (Invitrogen Carlsbad, CA), replated at a density of 1x106 
cells/150 cm2 flask, and again grown to confluence (P1). This process was repeated up to 
3 times to reach P4.  Those cultures treated with rhFGF-2 [FGF+] (R & D Systems 
Minneapolis, MN) received fresh growth factor added to the media at a concentration of 
1ng/ml at the time of passage from P1 until P4. 
 
Hydrogel culture 
For all experiments, 2% Pronova UP LVG sodium alginate (FMC Biopolymer 
Drammen, Norway) and 2% Agarose type VII (Sigma, St. Louis, MO) solutions were 
used.   Gels were prepared by mixing the alginate or agarose powder with calcium and 
magnesium free phosphate buffered saline (PBS).  The mixtures were autoclaved for 20 
minutes to dissolve the powder and sterilize the solutions.  
Cylindrical gels were cast in a custom designed mold (see Appendix B for mold 
design and seeding protocol).  The mold consisted of a solid base and top piece 
containing cylindrical holes machined from 0.25 inch thick polycarbonate.  A 0.2 µm 
cellulose-acetate membrane (Cole-Parmer, Vernon Hills, IL) supported by an 80 µm 
stainless steel mesh (McMaster Carr, Atlanta, GA) was placed between the top and 
bottom pieces.  The membrane was wet with either a solution containing 102 mM CaCl2, 
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100 mM NaCl, and 50 mM HEPES to crosslink alginate gels or PBS to support agarose 
gels while they polymerized.  At the specified passage, FGF+ and FGF- cells were 
suspended in the specified hydrogel at a seeding density of 20x106 cells/ml.  The gel plus 
cell solutions were pipetted into each well of the mold and allowed to polymerize for 30 
minutes at room temperature.  The resulting gels measured either 4 or 8 mm in diameter 
and were 2 mm thick.  Gels were rinsed in high glucose DMEM supplemented with 1% 
antibiotic/antimycotic (100 U penicillin G, 100 µg streptomycin sulfate, 0.025 µg 
amphotericin B/ml; Invitrogen Carlsbad, CA) after polymerization.  The constructs were 
then placed into either basal medium (DMEM supplemented with 1% ITS+ (BD 
Biosciences, Bedford, MA), 1% antibiotic/antimycotic, 0.1 mM non-essential amino 
acids (Invitrogen Carlsbad, CA), and 50 µg/ml ascorbic acid-2-phosphate (AA-2P; 
Sigma, St. Louis, MO), basal medium supplemented with dexamethasone-21-phosphate 
(Dex) or TGF-β1 plus Dex in the concentrations outlined below.  Gels were covered with 
1-2 ml of media and cultured in a humidified atmosphere of 5% CO2 at 37°C.  Media was 
changed every 2-3 days for the duration of the experiments.  Fresh AA-2P was added to 
the culture at every media change. Dex or TGF-β1 + Dex were also added fresh at every 





Experimental groups for all studies are outlined in Table 4.1.  In the first study, 
we examined the combined effects of growth factor treatment during monolayer 
expansion and alginate culture at P2 and P4 (Study A).  At each passage point, the cells 
were divided into 4 groups: Monolayer expansion with (Groups A1 and A3) or without 
(Groups A2 and A4) 1ng/ml FGF-2 supplemented media and then, after encapsulation in 
alginate, exposure to 10 nM Dex alone (Groups A1 and A2) or 10ng/ml TGF-β1 + 10 nM 
Dex (Groups A3 and A4).  Samples were harvested after 21 days of culture for 
biochemical and immunohistochemical analysis.  Next, we examined the effects of Dex 
concentration and hydrogel material on the production of cartilaginous proteins and cell 
viability (Study B).  P2, FGF+ cells were seeded in alginate or agarose and treated with 
10 ng/ml TGF-β1 and either 0, 0.1, 10, or 1000 nM Dex .  Samples were harvested after 
21 days for biochemical and live/dead analysis.  Finally, we investigated the effects of 
hydrogel on the chondrogenic response to a specific growth factor regimen: 1ng/ml FGF-
2 treatment during monolayer expansion and 10ng/ml TGF-β1 + 10 nM Dex treatment in 
3D culture (Study C).  P2, FGF+ and FGF- cells (Groups C1, C2 , and C4 and Groups C3 
and C5, respectively) were seeded in alginate or agarose.  They were then cultured in 
either basal medium (ITS alone) (Group C1), 10nM Dex alone (Groups C2 and C3), or 
10ng/ml TGF-β1 + 10 nM Dex (Groups C4 and C5).  Samples were harvested on days 14 




Table 4.1 Experimental groups 
 Groups Monolayer Expansion  Hydrogel Culture  
  Passage




1 2     + 
2 2     - 10 -- 
3 4     + 
Study A 





1 2     + 0  10 
2 2     + 0.1 10 
3 2     + 10 10 
Study B 





1000 10  
1 2     + ITS alone 
2 2     + 
3 2     - 
10 -- 
4 2     + 
Study C 







a All FGF+ received 1ng/ml FGF-2 from P0 until the passage number indicated 
 
Biochemistry 
 To assess the accumulation of a cartilaginous matrix, sGAG production was 
measured using the DMMB dye assay developed by Farndale et al. [194] and including 
modifications reported by Lee and Bader [195].  Total DNA was quantified using 
Hoechst 33258 dye (Sigma, St. Louis, MO) as described by Kim et. al [196].  On day 14 
or 21, whole alginate gels were digested with proteinase k in a buffer containing 100 mM 
sodium phosphate and 5 mM EDTA at 60°C for 16 hours.  Whole agarose gels were first 
heated at 70°C in ammonium acetate until softened, then cooled to 41°C for 1 hour 
before adding 1.5 U/ml agarase.  Samples were incubated at 42°C overnight to break up 





 Immunohistochemistry was used to confirm the production of the cartilage 
specific proteins aggrecan and collagen type II.  Alginate gels were rinsed in 100 mM 
barium chloride for 30 minutes under agitation to permanently crosslink the gels.  After 
rinsing in PBS, 1 mm sections were cut from the center of both alginate and agarose 
samples, placed in 48 well plates, and fixed in 10% NBF for 10 minutes.  All of the 
following steps were performed on a shaker plate.  Samples were rinsed with PBS and 
permeabilized with 0.01% Triton-X (Sigma, St. Louis, MO) for 5 minutes.    Samples 
were then treated with 0.05 U/ml chondroitinase (Sigma, St. Louis, MO) for 30 minutes 
at 37°C.  After rinsing, samples were blocked with 1% BSA (Sigma, St. Louis, MO) in 
PBS for 10 minutes.  Either primary monoclonal mouse anti-type II collagen (II-II6B3; 
Developmental Studies Hybridoma, Iowa City, IA) or polyclonal rabbit anti-aggrecan 
(AB1031; Chemicon, Temecula, CA) antibodies (diluted 1:1 and 1:40 respectively in 1% 
BSA/PBS) were then applied to the samples and incubated at room temperature for 1 
hour.  Secondary antibodies conjugated to Rhodamine Red (collagen) and Alexa Fluor 
488 (aggrecan) (Molecular Probes Eugene, OR) were diluted 1:200 in 2% serum and 1% 
BSA.  Hoechst 33258 dye (Sigma, St. Louis, MO) was also included in this solution at a 
concentration of 10 ng/ml to counterstain the cell nuclei.  Samples were incubated in the 
secondary antibody solution under low light conditions for 1 hour at room temperature.  
Images were taken on a Zeiss LSM 510 confocal microscope at excitation/emissions of 
365 nm/458 nm for Hoechst, 573 nm/590 nm for Rhodamine Red, and 496 nm/518 nm 
for Alexa Fluor 488.  Negative controls, incubated with secondary antibodies only, were 




 The Live/Dead Assay (Molecular Probes) was used to follow the progression of 
cell death within the gel samples over time.   The protocol was adapted from 
recommendations provided by the manufacturer.  Briefly, for each treatment group, the 
remainder of the gel from which the immunohistochemistry sample was excised was 
incubated in a solution containing 4 mM ethidium bromide and 4 mM calcein for 45 
minutes.  After rinsing in PBS, gels were imaged on a Zeiss LSM 510 confocal 
microscope.  Viability was determined by imaging three samples along the cross-section, 
rim, bottom, and top regions.  Twenty consecutive 5 µm thick images were taken from 
the cross-section of each sample and the number of live and dead cells in each image was 
counted using ImagePro software.   
 
Statistical Analysis 
 The effects of culture conditions on group means were assessed using the analysis 
of variance (ANOVA) general linear model.  Statistical significance (p<0.05) between 
individual group samples was determined using the Tukey post hoc test for multiple 











Passage dependent FGF-2 and TGF-β1 modulation of BMSC chondrogenesis 
 In our first study, the influence of passage number and FGF-2 treatment on rat 
BMSC chondrogenesis in alginate was examined.  Treatment with FGF-2 during 
monolayer expansion did not affect the DNA content of constructs after 21 days in 3D 
culture except for P4 cells treated with Dex alone (Figure 4.1A).  FGF-2 treatment 
significantly enhanced TGF-β1 stimulated chondrogenesis at P2, however this effect was 
lost at P4 (Figure 4.1B).  Exposure of constructs to TGF-β1 during 3D culture increased 
sGAG/DNA measurements at both P2 and P4.  Over all the groups, FGF-2 treatment 
during monolayer expansion and TGF-β1 treatment in alginate culture of P2 cells for 21 
days resulted in the greatest deposition of sGAG.  In addition to sGAG accumulation, 
collagen type II expression detected by IHC qualitatively confirmed chondrogenesis of 
rat BMSCs in response to TGF-β1 (not shown).  Based on the results of this study, P2 
cells were subsequently used to examine the effects of growth factor treatment regimen 





Figure 4.1. Effects of passaging on DNA and sGAG levels 
Cells expanded to P2 or P4 in the presence or absence of FGF-2 were seeded in alginate 
and cultured for 21 days. (A) Total DNA and (B) sGAG normalized by total DNA (n=4-
6). 
 
BMSC response to Dex treatment is scaffold dependent 
 In preliminary experiments, we observed that hydrogel constructs exposed to Dex 
appeared to have decreased cell viability.  To more closely examine the effects of Dex on 
BMSC viability and cartilaginous matrix deposition, a dose response study was 
performed (Figure 4.2).  At day 21, Dex treatment significantly decreased viability in 
agarose but not alginate constructs (p<0.008).  Images taken on the rim, top, bottom, and 
cut face of each construct demonstrated consistent distribution of live and dead cells.  In 
all agarose groups receiving Dex, there was an approximately 20% decrease in the 
number of live cells (Figure 4.2A).  No dose-dependent effect of Dex on cell viability 
was observed in either hydrogel group.  The samples receiving 10 nM Dex had an 
approximately 2 fold higher accumulation of sGAG over all other groups in both 



















































relative differences observed within the two hydrogel systems, alginate overall supported 
a higher level of sGAG accumulation compared to agarose (p<0.0012).   
 
 TGF-β1 + Dex Dex only 
Dex 




























Figure 4.2.  Dex dose response results 
 
[Top] Live dead staining of day 21 alginate and agarose gels treated with 0, 0.1, 10, or 
1000 nM Dex with or without the addition of TGF-β1.  Live and dead cells fluoresce 
green and red respectively.  The yellow regions are overlapping live and dead cells.  
Original magnification was 10x.  [Bottom] Cells expanded to P2 in the presence of FGF-
2 were seeded in alginate or agarose and cultured for 21 days in the presence of TGF-β1 
and the dosage of dex indicated. (A) Addition of Dex to agarose samples resulted in a 
20% decrease in cell viability compared to agarose samples that received no Dex 
treatment (n=5-6, § → p <0.008).   (B)  sGAG/DNA presented as the percent of the 10nM 
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BMSC response to chondrogenic growth factor regimen is scaffold dependent 
Having determined that P2 BMSCs treated with 10ng/ml TGF-β1 and 10nM Dex 
result in the highest accumulation of a cartilaginous matrix in alginate and agarose 
culture, we next examined the effects of hydrogel choice on the chondrogenic response of 
these cells to the entire growth factor regime:  1ng/ml FGF-2 during expansion to P2 and 
10 ng/ml TGF-β1 + 10 nM Dex during 3D culture.   
In both alginate and agarose constructs containing FGF+ cells, DNA content 
decreased in the ITS and Dex groups but remained similar in the TGF-β1 + Dex group 
between days 14 and 21.  TGF-β1 + Dex treatment of  FGF- cells stimulated a consistent 
increase in DNA between days 14 and 21 whereas Dex treatment alone had no effect on 
DNA content (Figure 4.3A & C).   
In alginate, FGF+ and FGF- groups treated with TGF-β1 + Dex had significantly 
more sGAG/DNA than either ITS or Dex alone at both days 14 and 21.  Alginate samples 
also had greater sGAG accumulation by day 21 compared to day 14 samples for all TGF-
β1 treatment groups (Figure 4.3B).  Additionally, FGF+ cells in alginate had increased 
sGAG accumulation over FGF- samples by day 21 only when exposed to TGF-β1 + Dex.   
Agarose samples treated with TGF-β1 + Dex demonstrated significantly more 
sGAG accumulation compared to ITS or Dex treatment alone only at day 21 (Figure 
4.3D).  In contrast to culture in alginate, FGF+ cells produced significantly less sGAG 
than FGF- cells in agarose by day 21.  At day 21, the amount of sGAG produced in FGF+ 
cells in alginate gels and FGF- cells in agarose gels cultured with TGF-β1 + Dex were 





                Alginate               Agarose  
 
 
Figure 4.3.  sGAG and DNA production 
 
Cells expanded to P2 in the presence or absence of FGF-2  were seeded in alginate or 
agarose and cultured for 14 and 21 days. (A&C) Total DNA and (B&D) sGAG 
normalized by total DNA (n=10-12).   
 
 
The live/dead images shown Figure 4.4 again demonstrate the negative effects of 
Dex on cell viability, particularly in agarose.  In alginate, FGF treatment during 








































































































the presence of Dex.  In agarose, neither FGF treatment nor TGF-β1 treatment appear to 
prevent loss of cell viability in constructs exposed to Dex over the 21 day culture period.  
 
 
Figure 4.4.  Live dead staining of alginate and agarose gels after 21 days of culture.   
 
The value below each image is the percent live cells as determined from image analysis 
of 20 consecutive confocal sections.  Original magnification was 10x.    
 
 
Aggrecan and collagen type II protein expression were most intense in TGF-β1 treated 
alginate and agarose samples.  Both proteins were localized to the pericellular matrix of 
individual cells or cell clusters (Figure 4.5).  There were no observable qualitative 
differences in aggrecan and collagen II expression in any of the TGF-β1 treated groups at 
either day 14 or 21, whether or not the cells were treated with FGF-2 during monolayer 
expansion.  
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Figure 4.5.  Immunohistochemical detection of collagen type II and aggrecan. 
 
Hydrogel samples containing cells treated with FGF-2 during monolayer expansion and TGF-β1 during 3D culture.  All 
images were taken at the 21 day timepoint.  Both proteins were localized in the pericellular regions surrounding single cells 







Ectopic and orthotopic small animal models are used extensively to evaluate cell-
based strategies for tissue repair and regeneration.  This study was a first step towards 
developing a small animal model in which bone marrow stromal cell based strategies 
may be initially tested for cartilage therapies.  The purpose of this study was to evaluate 
interactions between hydrogels and biochemical factors that stimulate chondrogenic 
differentiation of rat BMSCs.  Both alginate and agarose are promising scaffolds for 
cartilage tissue engineering.  However, these hydrogels are sometimes used 
interchangeably in tissue engineering research.  This study demonstrates that the 
chondrogenic response of BMSCs to biochemical chondrogenic stimuli is scaffold 
dependent.  Specifically, we found that rat BMSCs expanded in monolayer in the 
presence of FGF-2 resulted in a higher accumulation of a cartilaginous matrix in alginate 
culture in response to TGF-β1 treatment compared to TGF-β1 treatment alone.  
Conversely, FGF-2 expanded cells seeded in agarose accumulated less matrix than those 
cells exposed to TGF-β1 alone.  Additionally, we found that matrix accumulation was 
highest when an intermediate level of Dex (10nM) was added to the chondrogenesis 
media for both alginate and agarose culture.  However, Dex was also found to decrease 
cell viability in agarose constructs while having no effect on the viability of cells 
encapsulated in alginate.   
Although both alginate and agarose are composed of complex polysaccharides, 
their components give them very different physicochemical properties.  Alginate contains 
varying amounts of 1,4'-linked β-D-mannuronic acid and α-L-guluronic acid and the pore 
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size, diffusivity, and mechanical properties are determined by guluronic acid content and 
the method of polymerization [197].  The resultant gel is negatively charged.  Agarose is 
a neutral species composed predominantly of alternating units of β-D-galactopuranosyl 
and 3,6-anhydro-α-L-galactopuranosyl [198].  Due to the charge disparity between 
alginate and agarose as well as the differences in the structure achieved by their 
polysaccharide units during polymerization, the diffusion of molecules through these gels 
may be distinctive.  A study by Leddy et al. found that the porosity of 2% alginate and 
agarose were similar, however, the movement of negatively charged particles, such as the 
dexamethasone-21-phosphate used in these experiments, through alginate compared to 
agarose was not examined [199].  It is possible that alginate resists the diffusion of 
negatively charged particles into and out of the matrix exposing the encapsulated cells to 
a dissimilar biochemical microenvironment compared to agarose. 
Specific interactions between alginate and positively charged proteins have been 
reported in the literature [200].  These interactions are likely to also result in an altered 
cellular biochemical microenvironment in alginate compared to agarose samples cultured 
under identical conditions in vitro [200].  TGF-β1 has been shown to bind to alginate by 
replacing Ca2+, resulting in inactivation of the protein [200].  Wee et al. have shown that 
when TGF-β1-alginate is incubated in a low pH environment (e.g. waste buildup during 
metabolism) and then exposed to neutral conditions (e.g. media change), active TGF-β1 
is rapidly released from the alginate [200].  Cells seeded in alginate may therefore be 
exposed to varying levels of activated TGF-β1 depending on local pH.   
The propensity for positively charged proteins to bind to alginate may also 
increase the probability that cellular interactions with the scaffold will occur and 
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therefore alter their response to any growth factor regimen.  This phenomenon may 
explain why cells treated identically in monolayer have dissimilar responses to 
chondrogenic stimuli in alginate compared to agarose.  Surfaces and gels designed to 
contain specific proteins or present RGD sequences to cells have been shown to directly 
affect cell behavior [201, 202].  Furthermore, the binding of chondrocyte 
integrins to ECM molecules results in the intracellular formation of focal adhesion 
plagues, which is a prerequisite for cells to respond to growth factors such as FGF [203, 
204].  Studies comparing the in vitro response of chondrocytes to culture in various types 
of hydrogels have been reported [180, 183-185], but few have investigated the complex 
interactions of chondrocytes or BMSCs with these hydrogels on a sub-cellular level. 
Rat BMSCs have been used extensively in vitro to study the response of 
mesenchymal cells to osteogenic stimuli [159, 205-207].  However, chondrogenic 
differentiation of this cell population has only recently been examined, often with mixed 
results.  Hanada et al. found that they could not stimulate chondrogenesis in rat BMSCs 
using TGF-β1 in a pellet culture system [99], whereas Neuhuber et al. found that 
chondrogenesis could be stimulated using the pellet system with TGF-β3, BMP-2, and 
the addition of 1% FBS [149].  We found that rat BMSCs placed in alginate after primary 
confluence (P0) did not demonstrate significant sGAG production or collagen type II 
expression with TGF-β1 treatment (unpublished data).  This may explain the difficulties 
reported with chondrogenic stimulation of BMSCs derived from Sprague Dawley rats 
[99], however the monolayer treatment for the previous studies was not reported.  Studies 
examining the effects of passaging on stem cells derived from various tissues have 
demonstrated that the treatment of these cells in monolayer can effect their response to 
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differentiating conditions [148, 208].  We therefore examined the effects of passaging on 
rat BMSCs with a focus on the effects of FGF-2 stimulation.  We found that P2 cells 
underwent chondrogenesis in media conditions that P0 cells did not and that FGF-2 
treatment during monolayer expansion enhanced cartilaginous matrix accumulation over 
untreated cells. 
BMSCs have been shown to express the FGF-receptor [209] and the mitogenic 
effect of FGF-2 has been demonstrated in several cell systems including bone marrow 
progenitor cells derived from rabbit [148] and humans [148, 186, 209] as well as 
monolayer expansion of primary mammalian chondrocytes [186, 210, 211].  In 
agreement with these studies, we observed that FGF-2 treatment of rat BMSCs during 
expansion increased their rate of proliferation.  Additionally, FGF-2 expansion to P2 
stimulated increased subsequent sGAG production in alginate culture but did not have a 
significant effect on cells passaged to P4.  The interaction of FGF-2 and TGF-β1 in our 
system also corresponds with the previously reported response of rabbit and human 
BMSCs to chondrogenic factors.  The authors found that through multiple passages, cell 
expansion in the presence of FGF-2 resulted in greater sGAG accumulation in pellets 
treated with TGF-β1 [148].  In contrast, we found that the beneficial effects of FGF-2 on 
proliferation and sGAG accumulation of rat BMSCs decreased rapidly with passage 
number.   
The mechanism through which FGF-2 enhances differentiation of BMSCs is not 
yet known.  Hanada et al. hypothesized that FGF-2 increased the number of cells 
responsive to biochemical stimuli including Dex [159].  Martin et al. demonstrated that 
during monolayer expansion, bovine articular chondrocytes exposed to FGF-2 maintained 
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a spread morphology due to the disassembly of actin filaments.  These cells more readily 
recovered the chondrocytic phenotype compared to cells that did not receive FGF 
treatment [192].  In our study, rat BMSCs treated with FGF-2 also exhibited a more 
spread morphology than those that were not cultured in the presence of FGF-2.  This 
observation suggests that actin fiber arrangement within these cells prior to placement in 
a chondrogenic environment may have a role in rat BMSC chondrogenesis similar to 
primary articular cartilage chondrocytes. 
In both alginate and agarose, 10nM Dex resulted in the highest accumulation of a 
cartilaginous matrix.  These results are consistent with previous studies that demonstrate 
that Dex is either required for chondrogenesis or enhances matrix accumulation of 
cartilaginous proteins.  Grigoriadis et al. found that stem cells derived from rat calvaria 
required Dex treatment to undergo chondrogenesis and that cell clustering and matrix 
accumulation were dose dependent [190].  Derfoul et al. found that Dex treatment of 
human BMSCs upregulated sGAG production as well as increased the gene expression of 
aggrecan, dermatopontin, and collagen type XI.  The authors also reported that Dex 
enhanced TGF-beta-mediated upregulation of collagen type II and cartilage oligomeric 
matrix protein [189].  However, we also found that Dex resulted in a 20% decrease in cell 
viability in agarose cultures but not alginate cultures.  This scaffold dependence may 
again be due to differences in the diffusion of Dex through alginate compared to agarose 
or specific interactions of Dex with the hydrogels that is yet unknown.  
The precise mechanism through which Dex reduced cell viability has not been 
elucidated, but it has been shown to have a role in the regulation of chondrocyte 
phenotype and maturation in the growth plate [212], possibly through manipulation of the 
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IGF-I pathway [7, 108].  Work by Chrysis et al. using a human chondrocytic cell line 
demonstrated that Dex treatment in vitro increased the rate of apoptosis and that 
treatment with IGF-I abrogated this effect [213]. Our results also indicate that growth 
factor treatment, in our case FGF-2 and TGF-β1, may lessen the effects of Dex-induced 




This study demonstrates that TGF-β1 induced chondrogenic differentiation of rat 
BMSCs can be achieved in 3D hydrogel systems.  This response is cell passage 
dependent and expansion in the presence of FGF-2 enhances cartilaginous matrix 
accumulation within 2% alginate over time whereas FGF-2 pretreatment decreases matrix 
accumulation by BMSCs in 2% agarose.  Furthermore, Dex treatment is required for 






DELIVERY OF CHONDROGENIC STROMAL CELLS IN AN 
INJECTABLE HYDROGEL FOR THE REPAIR OF GROWTH 




The incidence of fractures in children have become more prevalent in recent years 
and, therefore, so has growth plate injuries [13].  Due to the variability of treatment 
options, growth disturbances caused by damage to physeal tissue still remains an issue in 
the orthopaedic field [1, 13, 56, 214-216].  This challenge has inspired the development 
of several animal models to investigate treatment strategies with a focus on the 
application of cartilage tissue engineering strategies to reform the damaged region of the 
growth plate and restore growth function.  These include the insertion of articular 
chondrocytes, growth plate chondrocytes, and stem cells [48, 49, 51, 52, 124].  In 
Specific Aim I, we showed that the delivery of an in situ gelling agarose to a centralized 
growth plate defect in a rat animal model decreased limb length discrepancies, but did not 
fully restore function to the injured area.  These results indicate that additional biological 
components are needed to fully restore growth function. 
Previous studies in animal models have demonstrated reformation of a growth 
plate tissue within the defect region when stem cells are introduced into a defect.  A 
scaffold is required for the full effect.  Comparison of adipose, ???, and BMSCs showed 
BMSCs are the best for cartilage fixing.  Histology and radiography at est for analysis. 
We therefore wanted to quantitatively evaluate the healing of growth plate defects using 
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the model and techniques developed in SA I to determine the differentiation based effects 
of introducing stem cells with in the defect. 
In Specific Aim II, we demonstrated that chondrogenesis of female Sprague 
Dawley rat BMSCs is dependent on cell passage, hydrogel culture environment, and 
growth factor regimen [217].  However, due to noted sex-specific response of progenitor 
cells to differentiation protocols in vitro and in vivo [218],  we chose to use male cells for 
implantation into the growth plate defect animal model.  We have demonstrated that male 
rat BMSCs are also capable of chondrogenesis differentiation using the optimal 
conditions found in Specific Aim II (Appendix C).  Studies in our laboratory have also 
demonstrated sex-based differences in the response of male rat BMSCs to alginate 
culture.  These studies demonstrate that, although these cells do undergo chondrogenesis 
when encapsulated in alginate, their viability decreases rapidly in this system (see 
Appendix D).   
Recently, interest has developed in applying a multi-step approach to 
chondrogenic pre-differentiation of bone marrow derived stem cells (BMSCs) [156, 219].  
Worster et al. found that equine BMSCs first stimulated with TGF-β1 in high density 
monolayer and then seeded in fibrin discs continued to accumulate sulfated 
glycosaminoglycans (sGAGs) once placed in hydrogel culture and that additional IGF-I 
stimulation in 3D culture enhanced matrix production [3].  Using human BMSCs, 
Matsuda et al. found that a cocktail of TGF-β3, IGF-I, and dexamethasone stimulate 
higher levels of aggrecan mRNA than cells seeded in 3D gel/polymer amalgams and that 
chondrogenic pre-differentiation of cells in 2D prior to seeding in 3D enhanced overall 
collagen II and aggrecan mRNA expression [220].  These studies demonstrate not only 
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that BMSCs undergo chondrogenesis in high density monolayer, but also that the 
chondrogenic phenotype is maintained after transfer to 3D culture and that pre-
differentiation in monolayer increased expression of chondrogenic markers and matrix 
accumulation over 3D culture alone. 
The overall objective of this specific aim was to deliver BMSCs pre-differentiated 
to the chondrogenic phenotype to centralized growth plate defects in the distal femur of 
Sprague Dawley rats for the correction of a growth disturbance.  The first aim of this 
study was to develop a method to initiate chondrogenic differentiation of male rat 
BMSCs that could then be seeded into a gel system for injection into cartilaginous 
defects.  We hypothesized that stem cells stimulated to undergo chondrogenesis in high 
density monolayer would retain their chondrogenic phenotype after transfer into an 
injectable in situ gelling agarose in vitro. The second aim was to deliver these cells to a 
growth plate defect via agarose injection.  Using the techniques and animal model 
developed in Specific Aim I, we quantitatively examined changes in growth plate and 
whole bone morphology in response to delivery of agarose and BMSCs.  We 
hypothesized that the degree of healing of the defect will depend on the differentiation 




Materials and Methods 
 
In vitro chondrogenesis of rat BMSCs in high density monolayer 
 
Cell isolation 
Bone marrow stromal cells were retrieved using a technique previously described 
[193].  Briefly, six male 45-day old Sprague Dawley (Charles Rivers Laboratory, 
Wilmington, MA) rats were euthanized by CO2 asphyxiation and their femurs and tibiae 
removed under IACUC approved guidelines.  Bone marrow was flushed from diaphyses 
with α-MEM supplemented with 1% antibiotic/antimycotic (100 U penicillin G, 100 µg 
streptomycin sulfate, 0.025 µg amphotericin B/ml; Invitrogen Carlsbad, CA) and a 
selected lot of fetal bovine serum (FBS; Hyclone, Logan, UT) using a 20 gauge needle 
attached to a 10 ml syringe.  The cell suspension was centrifuged at 1,200 RPM for 20 
minutes, resuspended in media, and plated at one leg/100 mm dish (Corning, Corning 
NY) for 30 minutes.  Unattached cells were collected, replated in 150 cm2 T-flasks at a 
density of 150x106 cells/flask, and covered with 35ml of media.  Media was changed 
after four days to remove non-adherent cells.  The cells grew in circular patches that 
became confluent after eight days, which were termed primary confluence (P0).  The 
cells were then lifted from the surface using 0.05% trypsin/0.53mM EDTA (Invitrogen 
Carlsbad, CA) and frozen until the experiment was performed.   
In Specific Aim II, we demonstrated that  female rat BMSC chondrogenesis was 
passage dependent.  Male cells exhibited a similar dependence in the chondrogenic 
environment.  Preliminary studies demonstrated that male cells expanded to P2 rapidly 
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die once placed in a chondrogenic environment whereas P1 cells remain viable.  
Therefore, all experiments in this specific aim were performed using P1 cells.  For the 
final expansion, cells were plated at a density of 6.67x103 cells/cm2 in either 185 cm2 T-
flasks for hydrogel seeding or 6 well plates (35mm dish) for a time-course analysis of 
chondrogenesis in monolayer. During this expansion, the passaging media was 
supplemented with 1ng/ml FGF-2 (R & D Systems Minneapolis, MN). 
 
Monolayer chondrogenesis  
 At confluence (P1), cells were switched to a basal chondrogenesis medium (high 
glucose DMEM with 1% antibiotic/antimycotic, 0.1 mM non-essential amino acids 
(Invitrogen Carlsbad, CA), and 50 µg/ml ascorbic acid-2-phosphate (AA-2P; Sigma, St. 
Louis, MO) supplemented with 2% FBS and either 10ng/ml TGF-β1 or 1ng/ml FGF-2.  
Samples were given 1.5ml media everyday.  Media samples and cells were taken on days 
0, 1, 2, 3, and 5 for sGAG and gene expression respectively. 
 
Hydrogel culture 
A solution of 1% SeaKem Agarose (Fisher Scientific) was prepared by mixing the 
agarose powder with calcium and magnesium free phosphate buffered saline (PBS).  The 
mixture were autoclaved for 20 minutes to dissolve the powder and sterilize the solution.  
Three-dimensional constructs were produced with either P1 cells released from 
monolayer culture with trypsin or cells that were stimulated in high density monolayer 
with TGF-β1 for 2 days. To isolate pre-differentiated cells, 185 cm2 T-flasks were treated 
with a cocktail of 0.3% dispase and 0.2% collagenase (Invitrogen) made up in α-MEM.  
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Flasks were agitated at 37°C for 30 minutes to release the cells.  Cells were then passed 
through a 70µm filter and the solution diluted with 3 volumes of α-MEM containing 10% 
FBS.  The cells were collected by spinning at 1200 RPM for 7 minutes, resuspended in 
PBS,  and counted on a hemacytometer. The cells were then resuspended in PBS at a 
density of 40x106 cells/ml. 
Cylindrical gels containing either undifferentiated P1 cells or TGF-β1-treated 
cells were cast as previously reported [217].  Briefly, cells in PBS were combined 1:1 
with 1% SeaKem agarose for a final cell density of 20x106 cells/ml in 0.5% SeaKem 
agarose.  The gel plus cell solutions were pipetted into a well of a custom designed mold 
and allowed to polymerize for 30 minutes at room temperature.  The resulting gels 
measured 4 mm in diameter and were 2 mm thick.  Gels were rinsed in high glucose 
DMEM (DMEM-HG) supplemented with 1% antibiotic/antimycotic after polymerization.  
The constructs were then placed into basal chondrogenesis medium  with the following 
supplements: (A) 10% FBS, (B) 1% ITS+ (BD Biosciences, Bedford, MA), or (C) 1% 
ITS+ and 10ng/ml TGF-β1.  Gels were covered with 1 ml of media and cultured in a 
humidified atmosphere of 5% CO2 at 37°C.  Media was changed every 2-3 days for the 
duration of the experiments.  TGF-β1 was added fresh at every media change. 
 
sGAG in the Media 
sGAG release into the culture media was measured using the DMMB dye assay 
developed by Farndale et al. [34].  Media samples (1ml) were lyophilized overnight and 
resuspended in 200µl water.  sGAG content was compared to standards containing 




For monolayer cultures, cells from 35mm wells were trypsinized, resuspended in 
3ml media, and counted using trypan blue exclusion.  Cell viability within agarose 
constructs  were determined using the Live/Dead Assay (Molecular Probes).  The 
protocol was adapted from recommendations provided by the manufacturer.  Briefly, 
samples were incubated in a solution containing 4 mM ethidium bromide and 4 mM 
calcein for 45 minutes.  After rinsing in PBS, gels were imaged on a Zeiss LSM 510 
confocal microscope.   
 
Histology 
Agarose construct were taken down on days 7, 14, and 21 for histological 
analysis.  Samples were fixed in 10% neutral buffered formalin at 4°C for 1 week and 
stored in 70% ethanol at 4°C until histologic processing.  Four micron sections were 
taken of paraffin embedded samples through the cross-section and stained with safrinin-O 
(Saf-O). 
 
RNA Isolation and Quantitative RT-PCR 
Cells in monolayer culture were rinsed with PBS and then covered with 350µl 
RLT buffer (Qiagen) containing 1% β-mercaptoethanol.  The cells were then scraped 
from 35mm dishes and disrupted by passing through a Qiashredder according to the 
manufacturer’s protocol (Qiagen).  RNA was isolated using RNeasy spin columns 
according to the manufacturer’s protocol.  One microgram of DNase-treated RNA was 
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converted to cDNA using the Promega Reverse Transcriptase kit (Promega).  Samples 
were probed for aggrecan, collagen type II, Sox9, and collagen type I using SYBR Green 
dye on a ABI PRISM 7700 system (Applied Biosystems) using the sequences listed in 
Table 5.2. 
 
Table 5.2. Quantitative PCR Primers 
Collagen Type II forward CTC AAG TCG CTG AAC AAC C 
Collagen Type II reverse CTA TGT CCA CAC CAA ATT CC 
Collagen Type I forward ATG TTC AGC TTT GTG GAC 
Collagen Type I reverse GGA TGC CAT CTT GTC CAG 
Aggrecan forward AGG ATG GCT TCC ACC AGT GC 
Aggrecan reverse TGC GTA AAA GAC CTC ACC CTC C 
Sox9 forward ACT TCC GCG ACG TGG ACA TC 
Sox9 reverse TGT AGG TGA CCT GGC CGT G 
 
 
Growth plate defect animal model 
 
Surgical Procedure 
All procedures were performed under Georgia Institute of Technology IACUC 
approved guidelines.  Sprague Dawley male rats (body weight 100-125 grams, 
approximately 5 weeks old) (Charles Rivers Laboratory, Wilmington, MA) were used in 
all studies.  Animals were anesthetized using 5% isoflurane and prophylactic antibiotics 
were administered by subcutaneous injection.  The skin over both knees sterilely prepared 
and draped, providing a sterile surgical field.  A 2 cm midline incision was made on the 
anterior aspect of the right knee joint and a medial parapatellar arthrotomy performed.  
The patella was dislocated laterally to expose the trochlear groove of the distal femur.  
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Using a hand drill, a central defect was created across the physes of the distal femur by 
drilling through the articular cartilage between the condyles, normal to the cross-sectional 
plane of the bone shaft, and then further up the intramedullary canal.  The depth of 
drilling into the metaphyses was controlled with a mechanical stop so that the defect did 
not enter the marrow cavity. The defect was made 2mm deeper than in Specific Aim I so 
that the Gelfoam inserted would be below the growth plate (see below).  The defect was 
then irrigated with a sterile saline solution and treated as outlined below.  The patella was 
relocated to its original position and the medial joint capsule was closed with 4-0 vicryl 
suture.  The skin was closed using wound clips and the surgical area was washed with 
hydrogen peroxide.  The wound clips were removed 10-14 days post surgery.  The left 
leg was left unoperated and used as the control for all analyses.  Animals were euthanized 
by CO2 asphixiation on day 56 (n=4 per group) post surgery.   
Gelfoam (Henry Schein) was inserted into each defect after rinsing with saline 
to stop blood infusion into the defect (see Appendix E for the effects of Gelfoam 
insertion into growth plate defects).  The defect was then packed with gauze.  After 20 
minutes, the gauze was removed and the site was checked for bleeding. The defects were 
then either left empty, filled with 0.5% agarose, filled with 0.5% agarose containing 
BMSCs pre-differentiated with TGF-β1, or filled with 0.5% agarose containing P1 
BMSCs.  All cells were suspended at a density of 20x106 cells/ml.   
 
Microcomputed Tomography 
The epiphyseal region of the defect legs were scanned at a 20 µm voxel size on a 
VivaCT 40 system (Scanco Medical, Bassersdorf, Switzerland).  The volume of bone 
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infiltration into the defect (bone bridge formation) was measured by isolating a 2 mm x 
15 slice (0.32 mm) cylindrical region within the original defect contained entirely within 
the growth plate as shown in Figure 5.1A.  This parameter was termed the  defect bone 
volume fraction (Defect BVF).  To quantify the effect of the defect on growth, whole 
femurs from the defect and contralateral control legs were scanned at a voxel size of 36 
µm and the lengths of the whole bone and diaphysis of each femur were measured from 
the rendered 3D images.  The diaphyseal length was defined as the distance from the 
lesser trochanter to the metaphyseal plate and the total length was defined as the distance 
from the greater trochanter to the edge of the femoral condyles (Figure 5.1B).  Finally, 
the growth plate was isolated from the surrounding bone tissue in the micro-CT images 
by manual contouring of 2D slices of sagittal images.  The contoured regions were 
compiled to render 3D images (Figure 5.1C).  From these images, total growth plate 
volume was calculated and thickness maps generated.  Thickness measurements were 
obtained by expanding spheres at distinct voxels within the 3D volume.  Total volume 
was determined by counting the number of voxels within the contoured region and 
multiplying the value by the voxel volume.  To determine the effect of the defect on the 
natural course of growth plate closure in Sprague Dawley rats, the volume of mineralized 





   
Figure 5.1.  Micro-CT Analysis. 
Images demonstrating (A) the method of determining the mineral content within the 
original defect.  A controlled volume was used for each sample.  (B) The diaphyseal and 
overall lengths of the contralateral and defect bones.  (C) The location, position and 
morphology of the epiphyseal growth plate within the distal end of the femur.  Note the 




The effects of culture conditions on group means were assessed using the analysis 
of variance (ANOVA) general linear model.  Statistical significance (p<0.05) between 
individual group samples was determined using the Tukey post hoc test for multiple 




TGF-β1 stimulates chondrogenesis in BMSCs in monolayer culture 
Cells treated with TGF-β1 detached from the plates after 2 days and remained a 
floating monolayer until day 5.  Due to this phenomenon, cell numbers could not be 
ascertained at day 5.  BMSCs in high density monolayer showed very little proliferation 













the culture period.  The decrease in cell numbers after day 1 was due to the inability of 
trypsin to adequately release the cells from the high density monolayer.  The viability of 
the isolated cells remained high in both FGF-2 and TGF-β1 treated samples whether cells 
were released with trypsin or dispase and collagenase  (Figure 5.2).  sGAG released into 
the media was higher in TGF-β1 cultures until after day 2 (Figure 5.3).  BMSCs treated 
with TGF-β1 also had significantly higher expression of aggrecan mRNA by day 1 and 
collagen type II  by day 2.  There was no significant expression of Sox9 or collagen type 







































Figure 5.2.  Total cell number and viability of cells in monolayer culture. 
Cells were trypsinized from 35mm plates and cell number and viability were determined 






                 
Figure 5.3.  sGAG released into the media 
* indicates difference from FGF treatment (n=6) 
 
       
 Figure 5.4. Time-course of mRNA expression of male BMSCs in alginate gels 
* indicates difference from FGF treatment (n=8) 
 





















































































































Cells released from day 2 TGF-β1 monolayer culture and P1 cells were seeded in 
agarose to determine if pre-differentiation of cells in monolayer culture influenced matrix 
accumulation in 3D.  After 21 days of culture in agarose, very little matrix was produced 
by pre-differentiated BMSCs in serum, ITS, or with continued TGF-β1 stimulation.  
Light Saf-O was seen only in P1 BMSCs treated with TGF-β1 for 21 days in agarose 
culture (Figure 5.5). 
  Treatment in 2D Culture 






























Figure 5.5.  Safrinin-O staining of day 21 agarose embedded BMSCs. 
P1 and cells pretreated in monolayer (2D culture) with TGF-β1 for 2 days (top) were 
embedded in agarose and further cultured in 10% FBS, ITS, or ITS + TGF-β1 for 21 days 
(side).  Original magnification = 20x. 
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BMSCs effect growth plate healing in a differentiation dependent manner 
To determine the effect of BMSC differentiation state on the healing of growth 
plate defects, P1 or pre-chondrogenic cells were suspended in 0.5% SeaKem agarose 
(AGA+Undiff and AGA+B1, respectively) and delivered into the defect.  These were 
compared to defects left empty or filled with agarose alone (AGA).   
After 56 days post surgery, there were no differences in the volume fraction of the 
bone bridge formed within the defect in any of the treatment groups (Figure 5.6).  The 
tether BVF of the defect growth plates in the empty and agarose alone groups was higher 
than their respective contralateral controls.  Defects that received cells in addition to 
agarose showed no increase in tether formation over their contralateral controls (Figure 
5.7).  The volume fraction of tethers of the empty groups was greater than all of the 
agarose treated defect samples.  The agarose group had a higher tether BVF than the 
agarose + undifferentiated cells group, but not the agarose + β1 treated cells group.  All 
groups had a thinner defect growth plate than their contralateral controls, but there was 
no effect of injection of agarose or agarose and cells on this parameter (Figure 5.8).  In 
all cases, the defect legs were shorter than their contralateral control leg.  However, the 
defect limbs of the agarose alone group and the agarose + undifferentiated cell group 

























             



































                Figure 5.7.  BVF of tethers throughout the growth plate. 
 
* indicates difference from defect leg; # indicates difference from the AGA + Undiff 
































Figure 5.8.  Average growth plate thickness. 
* indicates difference from defect leg; n=4 
 
 





















Figure 5.9.  Total length of defect and control legs. 
* indicates difference from defect leg; ‡ indicates difference from AGA group; # 












In this specific aim we have shown that male rat BMSCs express the chondrogenic 
genotype and phenotype in high density monolayer with TGF-β1 stimulation.  However, 
when these cells were placed in 3D agarose culture, they failed to produce a cartilaginous 
matrix even with continued TGF-β1 stimulation for 21 days.  When 0.5% agarose with or 
without a cellular component was implanted into growth plate defects, there was no 
reduction of bone bridge formation within the defect or restoration of growth plate 
thickness.  We also saw that there was no dependence of tether formation on the 
differentiation state of the implanted cells.  However, a differentiation dependent 
response in length discrepancy was observed.  Injection of undifferentiated BMSCs into 
growth plate defects resulted in a reduction of limb discrepancy over empty defects and 
we showed a trend indicating that implantation of these cells improved whole limb 
lengths over implantation of agarose alone or BMSCs pre-differentiated in high density 
monolayer culture prior to insertion in vivo.   
The observed dependence of limb length discrepancy on BMSC differentiation 
state is likely related to the observed behavior of these cells in 3D culture in vitro.  
Although delivery of pre-differentiated BMSCs into this defect model inhibited tether 
formation to control levels within the growth plate, the treatment did not restore growth 
function to the injured limb.  This is probably due to the inability of these cells to secrete 
a cartilaginous matrix once placed in agarose and further cultured in vitro.  The same 
response may have occurred in agarose in vivo, thereby preventing the cells from 
reforming a functional growth plate and correcting limb growth.  Interestingly, 
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implantation of undifferentiated BMSCs reduced limb length discrepancy compared to 
samples of empty defects (45% reduction) but not over limbs with defects filled with 
agarose alone (30% reduction compared to empty defects).  Additionally, the resultant 
reduction in limb discrepancy due to implantation of undifferentiated cells is 40% more 
than that groups receiving pre-differentiated cells.  Unlike pre-differentiated cells, 
undifferentiated cells demonstrated accumulation of some cartilaginous matrix after 
encapsulation in agarose and TGF-β1 stimulation for 21 days.  In vivo chondrogenesis of 
these cells may have allowed them to achieve some reformation of growth plate-like 
tissue, which contributed to some restoration of growth function.  Histological analysis of 
these samples is needed to further characterize the behavior of undifferentiated and pre-
chondrogenic cells in vivo. 
The transfer of BMSCs into growth plate defects did inhibit excess tether 
formation in this model, but unlike undifferentiated cells, pre-differentiated cells did not 
correct limb length discrepancies.  In fact, the length of limbs treated with pre-
differentiated BMSCs was less than those treated with agarose alone.  In Specific Aim I, 
we found that increased tether formation was highly correlated with limb length 
discrepancy.  The disconnection between these parameters may be due to the secretion of 
specific paracrine factors by the injected BMSCs.  It has been noted that the 
differentiation state of various cell types will determine their response to growth factors 
in vitro [166].  It is possible that the response to autocrine and paracrine signaling 
between the native tissue and the implant was uniquely different for each cell type.  This 
may have resulted in normal tether formation in both cases, but this did not lead to 
restored growth.  The process of tether formation has not been well recognized in the 
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literature.  Martin et al. used micro-CT imaging to measure the number and volume of 
tethers during normal growth of Sprague Dawley rats [166].  Tether formation has also 
been noted in the normal closure dynamics of dog, porcine, and human histological 
sections [167, 221].  Despite these studies, the biomolecular mechanisms through which 
tethers form or the change in tether formation due to injury has not been investigated.  
Studies examining the process of tether formation and cross-talk between the implant and 
native tissue is required to elucidate the relationship between tether formation and limb 
growth. 
A number of aspects may have contributed to the lack of in vitro matrix 
production of chondrogenic BMSCs seeded into agarose gels including the passage point 
and culture conditions.  Previously, we showed that chondrogenic differentiation of 
female rat BMSCs is passage dependant [217] and the passage dependence of BMSC 
differentiation has been previously reported in other species [148].  We have also have 
evidence that the chondrogenic differentiation potential of male and female cells is 
dissimilar (see Appendix C).  Sex-based disparities in the osteochondral differentiation 
of muscle derived progenitor cells has also been noted [218].  Passage 1, male BMSCs 
expanded in the presence of FGF-2 were chosen for this study due to their ability to 
maintain high viability in agarose culture in vitro (see Appendix D).  However, like 
female cells, there is likely an optimal point in male BMSC expansion for favorable 
chondrogenic matrix production.  The cells remained viable throughout the in vitro 
culture period (data not shown), so it is unlikely that cell death is the cause of the lack of 
matrix secretion.  Further optimization of the regimen of growth factor and/or steroid 
stimulation for monolayer expansion and 3D culture is required.  Additional study is also 
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required to optimize retrieval of the cells once chondrogenesis is achieved as the 
dispase/collagenase digestion of the chondrogenic cell layer may have also contributed to 
the inability of these cells to secrete a cartilaginous matrix. 
In this study, we have demonstrated a that delivery of BMSCs in agarose into 
centralized  growth plate defects occurs in a manner dependent on the differentiation state 
of the cells.  Undifferentiated BMSCs reduced limb length discrepancies whereas the 
BMSCs pre-differentiated to chondrogenesis using TGF-β1 did not.  However, none of 
the treatment groups fully corrected limb length discrepancy.  Recent studies have found 
that stem cells isolated from various tissues can contribute to growth plate healing in vivo  
[51, 52].  Similar to our study, Hui et al. demonstrated that BMSCs decreased limb length 
discrepancy, but did not completely restore function [51].  Chen et al. found that 
periosteal derived MSCs delivered in agarose generated a new growth plate and 
completely corrected angular deformity [52].  However, this was in a rabbit model where 
excision of the lateral portion of the defect was removed and little limb length 
discrepancy was seen [52].  Based on these studies and the results presented here, further 
work is needed to characterize not only the chondrogenic potential of MSCs from various 
sources, but also to determine the response of MSCs to the physiological factors that 




In this specific aim, we have demonstrated that the potential for BMSCs to reduce 
limb length discrepancy due to a centralized defect through the growth plate of the distal 
 
88 
femur is dependent on the differentiation state of the cells.  Specifically, delivery of pre-
chondrogenic BMSCs did not restore growth function compared to empty defects.  
Trends indicate that delivery of undifferentiated cells reduced limb length discrepancy 
over pre-chondrogenic cells and agarose alone.  Inclusion cells in the implant did reduce 
tether formation to control levels. However, this parameter did not correlate with limb 
length discrepancy.  This result suggests that injection of cells restored the natural 
process of growth plate closure in rats.  It also indicates that increased tether formation 
may be a by-product of growth plate injury and not associated with disruption of the 
growth potential of the tissue.  Therefore, treatments that affect tether formation within 









As delineated in previous chapters, growth plate injury may result in the 
formation of a bone bridge in the defect region that connects the epiphyseal and 
metaphyseal bone.  This damage can result in a limb length discrepancy or angular 
deformity that may lead to life long disability.  Patient reviews and animal models have 
demonstrated that current treatment methodologies, including fat interposition and whole 
physeal transfer, have limited success rates.  These studies also illustrate that current 
imaging modalities to correctly diagnose these injuries in the clinical setting are lacking 
accuracy.  Based on these findings, there is a need for a more effective treatment method 
for growth plate injuries.  First, however, it is essential to define the relationship between 
injury to the growth plate, changes in growth plate morphology, and loss of growth 
potential.  Therefore, the overall objective of this dissertation was to demonstrate the 
utility of microcomputed tomography (micro-CT) to quantitatively assess the changes in 
growth plate and whole bone morphology due to growth plate injury and to assess tissue 
engineering strategies to restore growth function in injured limbs.  To accomplish this 
goal, a surgical model of a centralized growth plate defect was established in the distal 
femur of adolescent Sprague Dawley rats.  Methods were developed using the micro-CT 
to quantitatively measure the volume fraction of the bone bridge within the defect, 
alterations in natural physeal growth dynamics (growth plate thickness, volume, and 
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closure dynamics through tether formation) and limb length discrepancy (whole bone and 
diaphyseal lengths).  In parallel, the in vitro effects of monolayer expansion, culture 
environment, and growth factor regimen on bone marrow derived stem cell (BMSC) 
chondrogenesis were examined to develop a tissue engineering construct for treatment of 
growth plate defects.  Finally, the animal model was used to assess the effectiveness of an 
in situ gelling agarose, with and without a cellular component, to restore natural growth 
plate morphology and growth function to the injured limb.  Specifically, we examined the 
effect of the differentiation state of implanted BMSCs on the healing of these defects. 
Due to several observations made during the course of this dissertation and 
recently in the literature,  several changes had to be made to the study design before we 
could test the differentiation based effects of stem cell delivery into growth plate defects.  
In Specific Aim II, we demonstrated that TGF-β1 induced chondrogenic differentiation 
of female rat BMSCs in 3D hydrogel systems.  This response was dependent on passage 
number, hydrogel scaffold choice, and growth factor regimen.  Passage two (P2) cells 
accumulated more cartilaginous matrix in a chondrogenic environment than earlier 
passages.  Expansion of BMSCs in the presence of FGF-2 enhanced cartilaginous matrix 
accumulation within 2% alginate over time whereas FGF-2 pre-treatment decreased 
matrix accumulation by these cells when encapsulated in 2% agarose.  However, recent 
studies have show that the differentiation behavior of stem cells is also dependent on the 
sex of the animal from which the cells were derived and the sex of the animal in which 
they are implanted [218].  Therefore, the chondrogenesis of male cells was examined for 
implantation into our male animal model.  The viability of male cells was also dependent 
on passage number and growth factor regimen.  Passage 1 (P1) cells exhibited higher 
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viability in hydrogel culture compared to P2 cells and with FGF-2 treatment during 
expansion.  However, after chondrogenic differentiation in hydrogel culture, only 20% of 
the cells retrieved for implantation were viable.  Therefore, in the final study, a high 
density monolayer system was developed to achieve chondrogenesis of male cells.  
Ninety-five percent of pre-differentiated cells retrieved from this culture system remained 
viable.  These cells were suspended in agarose for implantation into growth plate defects 
or continued culture in vitro.   
In the course of developing our tissue engineered treatment strategy for growth 
plate injury, we observed that 1% SeaKem agarose polymerized before a homogenous 
cell/hydrogel solution could be obtained and injected into defects.  Therefore, cells were 
delivered to growth plate defects via a 0.5% agarose solution.  We also observed that 
back pressure and bleeding within the defects inhibited adequate delivery of the in situ 
gelling agarose, limiting the effectiveness of this solution in conforming to the shape of 
the defect.  In order to reduce bleeding and pressure, Gelfoam, an antifibrolytic sponge 
used clinically to control bleeding within deep wounds, was inserted into the defect prior 
to injection of agarose. 
The results of this dissertation indicate that prevention of bone bridge formation 
within a growth plate defect was not as significant as previously thought in preventing 
limb length reduction in response to growth plate injury.  Only recently have stem cells 
been used to treat growth plate defects in an effort to reform a functional growth plate.  
The majority of the work in this field has focused on the implantation of a filler material 
to prevent bone bridge formation.  In this work, bone bridge formation was not a 
significant predictor of defect healing as no correlations to changes in growth plate or 
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whole bone morphological parameters were found.  Treatment of defects with 1% 
agarose reduced the limb discrepancy although it did not reduce the volume fraction of 
the bone bridge formation.  These results indicate that blocking bone bridge formation 
may not be significant in restoring growth function to injured growth plates.  These 
results may also explain the high variability (15-38%) of the Langenskiöld procedure in 
the clinical setting.  Reformation of the growth plate has not been reported with use of 
this procedure – only whether or not the bone bridge has reformed.   
Understanding the relationship between the parameters of growth plate 
morphology and final limb length will aid in developing treatment strategies.  In this 
dissertation we examined the relationship between growth plate and whole bone 
morphological parameters in healthy and injured growth plates.  A time-course study of 
our growth plate injury model demonstrated that a centralized defect caused significant 
stunting of the injured limb’s growth up to 112 days post surgery.  The percent reduction 
in limb length was found to be positively correlated to percent reduction in growth plate 
thickness (R2=0.88), percent increase in tether bone volume fraction (R2=0.78), and 
percent reduction in growth plate volume (R2=0.61).  These findings demonstrate that a 
centralized defect model in Sprague Dawley rats replicates limb length discrepancies of 
human growth plate injury in the distal femur and that limb length discrepancy is 
associated with changes in growth plate morphology. 
Healing of growth plate injury was shown to be dependent on the density of in 
situ gelling agarose injected into the defect. At 56 days post surgery, injection of a 1% 
agarose solution into the defect resulted in a 50% decrease in limb length discrepancy 
compared to defects left empty.  Growth plate thickness was also increased by 10% with 
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this treatment.  However implantation of a lower density agarose (0.5%) solution only 
resulted in a 20% reduction in limb length discrepancy and had no effect on growth plate 
thickness.  These results further support the correlation found between growth plate 
thickness and length discrepancy and indicate that 1% SeaKem agarose contributed to 
the restoration of limb growth, probably through providing some support for normal 
function of the remaining growth plate tissue.   
Correction of limb length discrepancy occurs in a manner dependent on the 
differentiation state of implanted BMSCs.  Inclusion of cells in the implant reduced tether 
formation to the level of their contralateral controls irrespective of cell differentiation 
state. However, this parameter did not correlate with reduction of limb length 
discrepancy.  Delivery of pre-chondrogenic BMSCs did not restore growth function 
compared to empty defects.  Trends indicate that the delivery of undifferentiated cells 
reduced limb length discrepancy over pre-chondrogenic cells and agarose alone.    These 
results suggest that treatment of growth plate injury with BMSCs restored the natural 
process of growth plate closure in rats.  It also indicates that increased tether formation 
may be a by-product of growth plate injury and not associated with disruption of the 
growth potential of the tissue.  Therefore, treatments that affect tether formation within 
the growth plate may not restore growth function.   
In conclusion, we have developed a small animal model of centralized growth 
plate defects in adolescent Sprague Dawley rats that demonstrates limb length 
discrepancies similar to that seen in the clinical setting.  We have also demonstrated that 
micro-CT imaging can be used to quantitatively monitor disruptions in the normal 
function of the growth plate.   The changes in growth plate morphology due to injury 
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were found to be correlated to overall growth disturbances when the defect was allowed 
to heal without intervention.  Using these techniques in combination with histological 
analysis, we have revealed preliminary mechanisms of limb length discrepancy due to 
growth plate injury.  We showed that premature thinning of the growth plate was due to 
disorganization of the cellular microarchitecture of the tissue.  There was a loss in 
proliferative cell columns and a decrease in the number of hypertrophic cells.  Since the 
hypertrophic zone is responsible for 45-60% of limb growth [2, 3], the loss of these cells 
is likely to be the significant contributor to the stunted growth of the defect limb.  Bone 
bridge formation occurred with or without treatment and had no effect on limb length 
discrepancies.  Tether formation is reduced with injection of BMSCs, but does not appear 
to be associated with growth disruption.  Consequently, treatments that focus on 
inhibiting bone bridge or tether formation are unlikely to correct limb length discrepancy.  
Future research should concentrate on maintaining the health of the remaining growth 
plate tissue. 
The techniques developed here contribute to the field in that they offer an 
improvement over basic histology for in situ analysis of alterations in growth plate tissue 
morphology due to injury.  Combining the animal model and the micro-CT analysis 
techniques developed in this dissertation with biological methods, such as in situ 
hybridization, will further our understanding of the mechanisms of growth plate repair 
and its relationship to limb deformities and can also aid in more accurate diagnoses of 
growth plate injury clinically as well as aid in surgical preparation for treatment of these 
defects.   
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Tissue engineering strategies using progenitor cells has gained interest in the 
research community for treatment of a wide variety of musculoskeletal injuries.  In this 
work, we have shown that several factors of rat BMSC chondrogenesis were interrelated.  
Cell viability and matrix accumulation were dependent on passage number, hydrogel 
scaffold, and growth factor regimen.  When BMSCs were implanted into growth plate 
defects, a dependence of limb length discrepancy on the differentiation state of these cells 
was observed.  This response appears to be due to the inability of pre-chondrogenic 
BMSCs to continue to secrete a cartilaginous matrix when placed in hydrogel culture.  
This work has contributed to our understanding of the interdependence of factors such as 
sex of the animal, passage number, scaffold choice, and final tissue engineering 
application on progenitor cell response to a chondrogenic differentiation protocol.  In 
future applications of BMSCs for cartilage tissue engineering, characterization of the 
interdependence of BMSC chondrogenic response to in vitro and in vivo conditions will 




This research has provided an important step toward understanding the 
relationship between growth plate morphology and growth disruption.  However, along 
the way several limitations have been uncovered and research questions raised.  One of 
the main limitations of our animal model is that the growth plate isolation protocol is 
time consuming and not practical for clinical application.  To address this issue, 
preliminary studies have been performed using Hexabrix (Mallinckrodt).  Hexabrix is 
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an injectable, iodinated, water soluble contrast agent  that is currently used clinically for 
angiography and arteriography.  It has been safely used in children.  Previous in vitro 
work has also demonstrated that quantitative assessment of 3D cartilage morphology is 
possible using Hexabrix and micro-CT imaging [222].  In the preliminary experiment, 
the distal ends of Sprague Dawley rat femur were immersed in a 25% (v/v) Hexabrix at 
37°C for 30, 90, and 150 minutes.  The growth plate were then isolated using a protocol 
developed from Scanco software to label and isolate the growth plate as show in Figure 
6.1.  The accuracy of this method was compared to the contouring method developed in 
Specific Aim I.  The results are shown in Figure 6.2.  Compared to the contouring 
method, the average thickness decreased significantly after 90 minutes in Hexabrix.  
The volume measurement was not different.  Based on these results, Hexabrix is a 
promising method by which the growth plate morphology can be accurately isolated.  
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Figure 6.2.  Changes in growth plate morphological measurements with increased time in 
Hexabrix. 
 
 Another avenue of treatment for growth plate injury that was not explored in this 
dissertation is the delivery of growth factors into the defect.  For instance, studies in 
craniosynostosis, a premature fusion of cranial sutures (cartilaginous tissue responsible 
for skeletal growth) that results in abnormal skull morphology, have identified TGF-β’s 
25% Hexbrix/30minutes  
Component Label 
Extract growth plate                       
 
98 
as having a dominant role in this disease [223-228].  Specifically,  studies in this area 
have demonstrated that delivery of TGF-β3 to sutures in animal models of 
craniosynostosis rescues osseous obliteration of this tissue by altering TGF-β2 and 
TGFR-β2 expression [224, 225].  In vitro studies have also shown that TGF-β3 acts 
directly on osteoblasts, inhibiting their activity [229].  TGF-β3 also shown to stimulate 
chondrogenesis in progenitor cells in vitro [230].  Therefore the presence of this factor 
within a cell/agarose construct may contribute to BMSC differentiation as well as 
blocking bone infiltration.  Based on these studies, a preliminary experiment was 
performed to examine the ability of TGF-β3 encapsulated in polymer nanoparticles to 
heal growth plate defects.  Approximately 1ng of TGF-β3 was injected into growth plate 
defects via 1% SeaKem agarose and the defect analyzed after 56 days.  The results 
show defect limbs did not show a limb length discrepancy (Figure 6.3).  However, there 
is no discernible effect when compare to defects left empty or filled with agarose alone.  
This study demonstrates that delivery of TGF-β3 into the defect may be beneficial to 
recovery of a normal limb length.  Further analysis with a larger sample, higher doses, 
and, possibly, combination with BMSCs may show complete healing of a centralized 




















Figure 6.3.  Effect of TGF-β3 loaded nanoparticles suspended in agarose on defect bone 
limb length. 
n=3; error bars=±SEM; * indicates difference from defect leg 
 
 
Finally the micro-CT method developed in this dissertation may be used to study 
growth plate abnormalities in diseases such as achondroplasia, the most common form of 
human dwarfism.  This disorder has been shown to be due to point mutations in the 
transmembrane domain of fibroblastic growth factor receptor 3 (FGFR-3) [103, 231].  
The morphological changes of the growth plate have been investigated through 
histomorphometric analysis of mouse knockout models [231, 232].  This method is both 
expensive and time consuming.  With techniques developed in this dissertation, in situ 
analysis of knockout models is possible and will allow investigators to study the time-
course of growth plate morphological changes in disease and with treatment.  We have 
recently demonstrated that the micro-CT method developed in this dissertation can be 
readily adapted to mouse growth plate using a vitamin D receptor knockout model (VDR-
/-) [233].  Significant differences in growth plate thickness, volume, and tether formation 




As enumerated in Chapter 2, many investigators are studying the control of 
progenitor cell differentiation for tissue engineering applications.  Numerous 
combinations of growth factors and scaffolds have been tested and developed for this 
purpose.  From this dissertation, four salient factors were found to play a role in the in 
vitro chondrogenic response of rat BMSCs: monolayer expansion, gender, hydrogel, and 
growth factor regimen.  These factors in no way cover the wide spectrum of facets that 
regulate the behavior of BMSCs, but has raised some interesting avenues worth pursing.  
For instance, the mechanism of dexamethasone (Dex)-induced cell death in agarose 
cultures.  Dex has been shown to have a role in the regulation of chondrocyte phenotype 
and maturation in the growth plate [212] and that it may be interconnected to the role of 
IGF [7, 108].  If BMSCs are to be introduced into the growth plate environment, than the 
effects of the factors that regulate growth plate morphology on differentiation and 
subsequent cell behavior requires further investigation.  Specifically, determining 
whether the maturation of chondrogenic BMSCs can be controlled though exogenous 
exposure to PTHrP, IHH, TGF-β, and BMP-6 would further demonstrate the 
chondrogenic phenotype of these cells and allow investigators to better predict their 







A. 1. Growth plate isolation from micro-CT scans 
 
 
1. Evaluate the epiphysis of the leg of interest in a voi window (this give you a 3D 
image without doing any evaluations): 
a. In Session Manager, click on IPL_VIVACT  
 
→ Change IPL_VOI_ONLY.com file to 1.2, 2, 92 
 
b. In the DECterm window type $ voi    
 → evaluation window opens up  
 → click “evaluation 3D”  
 → select the slice range of interest and make sure the white voi box  
 includes all of the regions of interest while still being as small as possible  
  
 → set the number of pages to zero or you will get a textbook of nonsense  
 from  the printer 
 → evaluate (record gobj file number if one is necessary; record the  
 seg.aim number.  You will develop several of both file types and will  
 need to keep them in order) 
 
2. Rotation of epiphyses: 
a. Open 3D window 
b. File→Open→measurement number→seg.aim number 
c. Orient the image such that the the posterior side of the femur faces out of the 
screen, towards the viewer (in the +y direction).  
 
Note:  The rotation and elevation shown in the upper left corner of the screen.  
These values  
correspond to the angles that the image must be rotated in the z and x directions, 
respectively. 
 




d. To rotate image 






+  rotation  
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IPL> read in DSK0…seg.aim  (image to be rotated) 
IPL> turn2d (around z-axis → ALWAYS DONE FIRST)  
 [in]> in [default values are in brackets and do not necessarily have to be 
changed] 
 [out]> out 
 [angle]> rotation value from 2c 
 





 [in]> out (from previous step) 
 [out]> rot (whatever you want) 
 [axis]> [default is x-axis: 0 90 90; y-axis: 90 0 90; z-axis 90 90 0] 
 [angle]> [default is 0.00] elevation angle from 2c if around x, rotation in  
 the plane of the screen if around y (you’ll have to approximate this one by  
 eye). 
 
- Hit enter until program is running 
 
e. To make the size of image as small as possible, the empty space is removed: 
 
 IPL> bounding 
  [in]> rot (or whatever you named the last out file) 
  [out]> cut 
 
- Hit enter until program is running 
 
f. Write rotated file to disk 
 
IPL> write cut DSK0…NEWNAME.aim (the NEWNAME should be the angles 
about which you rotated the image [e.g. X-10_Y5_Z130.aim]) 
 
g. Check rotation in the 3D window.  Repeat turn2d and turn3d as needed until the 
epiphysis is oriented like the image in step c. 
 
 
3. Creation of 2nd isq to contour growth plate. 
a. Rotate the image -90° around the x-axis 
b. Invert the image 
 
IPL> read in DSK0…seg.aim  (or just use ‘out’ file from last step) 
IPL> set_value out 0 127  
 




Note:  the image in ‘out’ has been replaced with the inverted image  
 
c. Create new ISQ. 
 




aim_name  [out]> out 
isq_filename  [default]> DSK0…isq (MUST be the isq from the sample 
file which contains your seg.aim file; MUST delete the 1) 
square_flag  [false]> leave at false (hit return) 
original_position  [true]>false (MUST be false) 
 
- Hit enter until program is running 
 
4. IF the new ISQ has more slices then the original:  
a. In DECterm window, create a new database and write down the new sample 
number applied by the system 
b. Then: $run_um:µCT_import 
Give the newly created isq file  
Enter the new sample number 
 
5. Contour the growth plate 
a. Open new isq in a VOI evaluation window 
b. SAVE OFTEN!  The buffer fills up quickly and you will lose data if you do not. 
c. Evaluate the growth plate  
i. Change the values in the IPL_VOI_ONLY.com file to 1.2, 2, 248 
ii. See 1b 
d. When all contours are drawn, delete all the .GOBJ files except those used to make 
the voi of the bone earlier and the very last GOBJ for the growth plate evaluation 
Write down the number GOBJ number. YOU WILL NEED THEM LATER. 
 
6. Determine growth plate thickness 
 
IPL> read in DSK0…seg.aim  (growth plate seg.aim) 
IPL> dt_obj  
aim_name  [in]> in 
output   [out]> out (whatever you want) 
gobj_filename  [default]> DSK0…gobj (the growth plate evaluation file) 
peel_iter  [-1]> this value must be determined prior to running this command 
 
- Hit enter until program is running 
 
IPL> write out  DSK0…GP_THICKNESS.aim (yields the color thickness  
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map) → (can be viewed in the 3D window) 
 
7. Determine bone volume fraction of the growth plate  
 
IPL> read in DSK0…seg.aim  (growth plate seg.aim) 
IPL> vox 
aim_name  [in]> in 
gobj_filename  [default]> DSK0…gobj (the growth plate evaluation file) 
peel_iter   [-1]> this value must be determined prior to running this  
command 
 
- Hit enter until program is running 








Purpose:  To rotate, invert, and convert to isq a seg.aim of an epiphysis.  Script saves 
rotated and inverted files in the folder of the seg.aim in question.  The input MUST BE a 
seg.aim file.  If it is not, copy the file of interest and rename _seg.aim. 
$!       
$!         _/_/_/  _/_/_/    _/         
$!          _/    _/    _/  _/           Image Processing Language   
$!         _/    _/_/_/    _/  
$!        _/    _/        _/             (c)  Andres Laib, Scanco 
Medical AG 
$!     _/_/_/  _/        _/_/_/_/             
$!               
$! 
$!  IPL Batch Scanco 
$! 
$   if p1 .EQS. ""  
$  THEN  
$ write sys$output "Give C0001234.aim ! Exit" 
$  exit 
$   endif 
$ 
$   define   org_file    'p1' 
$   turn_file = p1 - F$PARSE(p1,,,"VERSION") - "_SEG.AIM" + 
"_rotated.aim" 
$   inverted = p1 - F$PARSE(p1,,,"VERSION") - "_SEG.AIM" + 
"_inverted.aim 
$   isq_file = p1 - F$PARSE(p1,,,"VERSION") - "_SEG.AIM" + ".isq" 
$  
$   show log org_file 
$! 
$   ipl_scanco_prog := $um:ipl_scanco_m.exe 
$! 
$   ipl_scanco_prog 
 
 
/aim in org_file 
 
/turn3d in out  
 -turnaxis_angles   0 90 90      
 -turnangle         -90 
 
/bounding_box out cut 
 
/write cut "turn_file 
 
/set_value cut 0 127  
 
/write cut "inverted 
 
/from_aim_to_isq cut  
 -isq_filename          "isq_file 
 -square_flag           true 


























To promote rat osteoprogenitor cells to undergo chondrogenesis in alginate gels and 
agarose gels by stimulation with TGF- and dexamethasone.  
 
Materials 
Sterile 3% Pronova alginate made up in ion free PBS and autoclaved for 20minutes 
[FMC BioPolymers]  
Sterile 4% Type VII agarose made up in ion free PBS and autoclaved for 20minutes 
[Sigma] 
10 Sterile molds set up for alginate gels (metal mesh + filter paper) 
10 Sterile molds set up for agarose gels 
TGF-β1 [R&D Systems #240-B]     Lot#________________________ 
DMEM-High glucose [Gibco # 11995-073] 
10mM Non-essential amino acids (NEAA) [Gibco #11140-050] 
100X Antibiotic/Antimycotic [Gibco # 15240-062] 
L-proline [Sigma #P-1428 ] 
Ascorbate 2-phosphate [Sigma # A-8960] 
Dexamethesone [ICN #157565] 
ITS [BD Labware #354352]    Lot#____________________________ 
Selected lot of  FBS [Hyclone FLL1524; heat inactivated] 
 
Solutions 
Alginate crosslinking solution: 102 mM CaCl2, 100 mM NaCl, and 50 mM HEPES 
1,000X Stocks: 40mg/ml L-proline, 50mg/ml AA-2P, 10µg/ml TGF-β1, 10µM/ml Dex. 
Store at -80°C.   
DMEM+:  to DMEM-HG, add, 1% NEAA, 1% Antibiotic/Antimycotic, 40µg/ml L-
proline, and  
1% ITS. This solution is good for 3 weeks at 4°C.  At every feeding add, 50µg/ml AA-





1. Wet filter paper on molds with the alginate crosslinking solution.  Do this from 
the outside and allow to wick in. 
2. Count cells.  Determine how much 2% alginate solution will be needed to obtain a 
final density of 20x106 cells/ml. 
3. Spin down cells and resuspend in 1/3 of 2% alginate volume Ca2+/Mg2+ -free 
PBS.  Carefully 2/3 of 2% alginate volume 3% alginate to make a 2% solution.  
4. Seed alginate gels as per the experimental protocol.   
5. Place gels in 48-well plates. 
6. Add 1ml of media to the gels. 
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7. Place 6 in individual, preweighed Eppendorf tubes. Take wet weights and store at 
-20°C until assay.  
8. Stain 1 gel for the live/dead assay. 
9. Replace media every other day. 
10. Freeze remaining cells. 
 
Agarose 
1. Wet the filter paper with Ca2+/Mg2+ -free PBS.  Do this from the outside and 
allow to wick in.  Place molds (6) and 100 and 1000µl tips in to incubator for at 
least ½ hr. 
2. Resuspend cells in DMEM+ for a final seeding density of 40x106 cells/ml.  
Maintain at 37°C at all times. 
3. Microwave agarose for 10 sec. 
4. Add 500µl of 4% agarose to 4 sterile 5 ml tubes and place in a beaker.  
1. Place 1 tube of agarose at a time into a 42°C waterbath for no more than ½ hr.  
Also place a second container of water into bath to take into hood. 
5. Place the beaker containing 42°C water in the hood.   
6. Quickly add 500µl of the cell solution to a tube containing agarose using 
prewarmed tips and mix well.  Place in the water bath in the hood. 
7. Quickly seed agarose gels: draw up 27µl of agarose+cell solution and add to each 
well. 
8. Repeat until all gels have been seeded (stagger 15 minutes). 
9. Allow to polymerize in hood for at least 10 minutes.   
10. Place gels in 48-well plates. 
11. Add 1ml of each media to 24 of the gels. 
12. Takedown 6 gels for day 0 analysis and stain 1 for the live/dead assay. 
13. Replace media every other day. 











To determine the response of male rat BMSCs to TGF-β1 stimulation compared to 
female rat  
BMSCs 
2. Methods 
a. Cells were expanded to P2 in the presence of 1ng/ml FGF-2 
b. P2 cells were seeded in 2% alginate (25µl gels) 
c. Groups: 
ii. 10ng/ml TGF-β1 
iii. 10ng/ml TGF-β1 + 0.1nM Dex 
iv. Dex alone 
3. Analysis: 
a. sGAG/DNA – DMMB dye assay 
b. Live/Dead assay 
4. Results: 
a. sGAG/DNA – male cells accumulated more sGAG than female cells in response 
to TGF-β1 stimulation on days 14 and 21.  With Dex, there was only a difference 

















































Figure C.1.  sGAG production male and female BMSCs under chondrogenic conditions 
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b. Live Dead – Cell viability was high except in the Dex alone group 
 
 























   
 
Figure C.2.  Viability of male and female BMSCs under chondrogenic conditions 
 
5. Conclusions: 













1. Purpose to determine whether alginate culture or TGF-β supplementation causes 
death of male BMSCs during chondrogenesis  
2. Methods 
a. Frozen P0 cells were plated in T-185 NUNC plates at a density of 1x106 
cells/plate.  All plates were cultured in standard passaging media (α-MEM, 10% 
FBS, antibiotic/antimycotic) supplemented with 1ng/ml FGF-2 during monolayer 
expansion.  At P2, cells were seeded in the following conditions: 
i. Plated in 6 well plates at a density of 6.7x106 cells/cm2 and culture in the 
following media conditions: 
1. Basal media  
2. Chondrogenic media (CGC) – inclusion of 10ng/ml TGF-β  
3. Basal or CGC media with unpolymerized 2% alginate 
ii. 2% Pronova alginate at a density of 20x106 cells/ml in basal or chondrogenic 
media 
iii. 2% agarose at a density of 20x106 cells/ml in basal or chondrogenic media. 
b. Cell viability was examined on days 1 and 7 using the Live/Dead Assay 
3. Results (Figures D.1) 
a. Cells survived process of hydrogel encapsulation (Day 1) 
b. Cell viability was lost in monolayer and 3D hydrogel culture by day 7 with or 
without chondrogenic media. 
2. Conclusions 
a. Neither hydrogel nor growth factor stimulation is the singular factor that 
determines the viability of male BMSCs in culture. 
 
 



















No cells  
remaining 









No cells  
remaining 
   
               Figure D.1.  Viability of male BMSCs under various culture conditions 
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D.2. Effects of passaging, culture plate, and growth factor supplementation on the 
viability of male BMSCs during chondrogenesis in alginate gels 
 
 
1. Purpose to determine what culture condition affect cell male BMSC viability during 
chondrogenesis  
2. Methods 
a. Frozen P0 cells were plated in T-185 NUNC plates at a density of 1x106 
cells/plate.  All plates were cultured in standard passaging media (α-MEM, 10% 
FBS, antibiotic/antimycotic) supplemented with 1ng/ml FGF-2 during monolayer 
expansion.  At P1 and P2, cells were seeded in 2% Pronova alginate at a density 
of 20x106 cells/ml.   
b. 50µl gels were made in all cases.  The following conditions were examined: 
i. Passage point – Cells at Passage 1 and 2 were used in all conditions 
ii. Incubator – cells were cultured in my incubator and another incubator that not 
previously used for chondrogenesis culture 
iii. Culture media – ITS alone and TGF-β (CGC)  
iv. Time in culture – viability was determined on days 1, 3, and 7 
v. Type of culture dish – gels were cultured in a group in 25cm2 T-flask.  Gas 
exchange occurs through a filtered cap. Gels were cultured individually in a 
24 well plate. Gas exchange occurs with the incubator air directly. 
3. Results and Conclusions (Figures D.2 and D.3) 
a. Passage point – P1 cells appeared less spread and proliferated faster than P2 cells.   
b. Incubator – No differences were observed 
c. Culture media – TGF-β treated gels had more viable cells in each sample that ITS 
alone samples at P1.  These differences were less apparent at P2. 
d. Time in culture – At P1, cell viability did not appear to decrease from day 1 to 
day 3, but does decrease from day 3 and day 7.  P2 cell viability appeared to 
decrease rapidly from day 1 to day 3. 
e. Type of culture dish – individual culture in plates may have some benefit on cell 
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Figure D.2.  Viability of P1 male BMSCs encapsulated in alginate gels under various 
culture conditions over time.  
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Figure D.5.  Viability of P2 male BMSCs encapsulated in alginate gels under various 
culture conditions over time. 
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1. Purpose to verify that male BMSCs remain viable in 0.5% SeaKem agarose for 
delivery into growth plate defects. 
2. Methods 
a. Frozen P0 cells were plated in T-185 NUNC plates at a density of 1x106 
cells/plate.  All plates were cultured in standard passaging media (α-MEM, 10% 
FBS, antibiotic/antimycotic) with or without 1ng/ml FGF-2 during monolayer 
expansion.  At P1 and P2, cells were seeded in 0.5% SeaKem agarose at a 
density of 20x106 cells/ml.   
b. Samples were harvested on days 0, 3, and 7 for live/dead analysis 
3. Results (Figures D.4) - P1 cells seeded in agarose remained highly viable at all 
timepoints with or without FGF-2 supplementation.  Cell death increase in P2 cells 
seeded in agarose over time. 
4. Conclusion – P1 cells will be used in vivo for the repair of growth plate defects. 
 
 








































Figure D.4.  Viability of male BMSCs passage with FGF-2 supplementation and culture 







E.1.  Effect of Gelfoam insertion into growth plate defects in Sprague Dawley rats 




Previous studies indicated that bleeding from the marrow cavity was preventing 
agarose injected into the defect from fully conforming to the defect site due to mixing 
and/or back pressure from the marrow cavity.  Hence antifibrolytic agents such as 
aprotinin, ε-amino caproic acid, and tranexamic acid were compared to 
Gelfoam to determine which would clot the defect and allow for full conformal 
filling of the defect by injected agarose.  Preliminary studies indicated that Gelfoam 
was the most successful.  In this study, the effects of Gelfoam on the natural healing 
response of the defect model was examined. 
2. Methods 
a. A defect was created in the distal femur of both legs in each rat (n=3) with the 
right leg receiving treatment a 2mm plug of Gelfoam.  The plug was pushed 
into place below the growth plate using a rod with a mechanical stop.  The defect 
was then stuffed with dry cotton for 10 minutes.  The defect in the left leg 
received no treatment.   
b. Both defects were left empty for 28 days.  Baseline healing was defined as the 
final total and diaphyseal lengths of the bones receiving Gelfoam versus the 
contralateral control. 
3. Results 
a. No effect of the presence of Gelfoam on the base healing response of growth 
plate defects after 28 days.  However, the presence of Gelfoam did decrease the 
BVF in the growth plate region by ~50% (paired t-test, p<0.02). 
4. Conclusions 
Gelfoam insertion decreases BVF within the defect while having no effect on limb 




































































E.2.  Comparison of 1% and 0.5% SeaKem agarose on growth plate defect healing 




To determine whether or not the density of agarose injected into the defect had any 
effect on limb length shortening.  A step toward specifying the gel composition in 
which cells will be introduced into the defect. 
2. Method  
a. A defect was created in the distal femur of both legs in each rat (n=3) with the 
both legs receiving treatment with 100mg/ml tranexamic acid for 10 minutes to 
stop bleeding.   
b. Both defects were filled with 0.5% (right) or 1% agarose (left).  Samples were 
harvested after 28 days. 
3. Results 
4. No differences in limb leg or BVF between defects filled with 0.5%  agarose 































Figure E.26.  Effect of agarose density on growth plate defect BVF and limb length 
28 days post surgery. 
 
5. Conclusions 
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